CONFIDENTIAL 
The information contained in this document is regarded as confidential, and may not be disclosed to another party unless such disclosure is 
required to initiate the study, to conduct study -related activities, or to comply with national, state, or local laws and regulations.  Written 
authorization from the coordinating site and sponsor is required for disclosure otherwise.  The Preston Robert Tisch Brain Tumor Center  
Duke University Medical Center 
A Phase II Study  
 
Phase II randomized study to evaluate efficacy, patient satisfaction, and 
compliance of the oral combination of Rolapitant (Varubi®) plus ondansetron vs. 
ondansetron monotherapy in malignant glioma patients receiving radiotherapy 
(RT) and concomitant temozolomide  
[STUDY_ID_REMOVED] 
 
     
 Sponsor:   PI – Duke Cancer Institute   
 Funding Source:  TerSera Therapeutics    
 Protocol Source:  PI – Duke Cancer Institute   
 Duke IRB#:  Pro000 76418   
 IND#  
Protocol Version Date:  133107 (Exempt)  
February 18, 2022   
                                                                                             
 
Principal Investigator  
Mary Lou Affronti D.N.P., R.N., 
A.N.P., M.H.Sc  
047 Baker House  
DUM C 3624, Durham N.C., 27710  
919-684-6239  
919-684-6674  
affro002@mc.duke.edu  
 Co-Principal Investigator(s)  
Katherine Peters, M.D., Ph.D. 
katherine.peters@dm.duke.ed u 
047 Baker House  
DUMC 3624, Durham N.C., 27710  
  
Sub-Investigator(s) 
Annick Desjardins, M.D., F.R.C.P.C  
annick.desjardins@dm.duke.edu  
 
Margaret Johnson, M.D.  
margaret.o.johnson@duke.edu   
 John Kirkpatr ick, M.D., Ph.D.  
john.kirkpatrick@duke.edu  
 
Henry Friedman, M.D.  
henry.friedman@dm.duke.edu  
 
Mallika Weant , PharmD  
mallika.weant@duke.edu   
Statistician  
James E.  Herndon II, Ph.D. 
james.herndon@dm.duke.edu  
 Lead Study Coordinator  
Erin Severance  
erin.k.bell@.duke.edu  
 
Regulatory Coordinator  
Kendra Boyd  
kendra.boyd@duke.edu  
 Data Manager  
Eric Lipp  
eric.lipp@dm.duke. edu 
 
 
Original version:  Date  11/29 /16  
Amended version:  Date  01/12/17  
 
 Lead study coordinator changed, r olapitant dose (180 mg) added to 
study schema  (Section 6)  and study design (Section 9.1) .  Extensive 
information on past palonose tron study was removed in sections 

PT-PhII or III v04.30.14  Duke Cancer Institute  Page 1  of 52 
CONFIDENTIAL 
  
 
 
 
  
Date 8/8/17  5.2, 7.1, and 7.3 .  A clarification of a total of 80 randomized 
patients for interim analysis was added to section 15.6.   Primary 
endpoint and KEY secondary endpoint clarification to headings in 
section 15.7.  Hyperlinks modified appropriately.  
 
Updated eligibility to include patients that may want to participate 
in a clinical trial AFTER standard of care radiation and temodar 
(Section 5.4 and 11.2 ).  Removed redundant inclusion criteria 
(Section 5.4 and 11.1 ).  Removed excess pregnancy tests ( Table 7).   
 
 
 Date 2/ 19/18 
  
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
Date 1/31/19 Added ECOG to inclusion criteria, removed redundant radiotherapy 
criteria that is covered by the broad criteria – “prior cancer 
chemotherapy or radiotherapy” in exclusion criteria, removed urine 
pregnancy test from exclusion criteria because only ser um 
pregnancy test will be used (Section 5.4 and 11).  Removed SGOT 
from Inclusion Criteria #5 given th at AST limits are set in Inclusion 
Criteria #6 (Section 11.1).  Removed the “Xs” from the Adverse 
Events line and replaced it with continuous, added urinalysis , 
removed medication log from screening,  increased screening 
period to 4  weeks , and added a footnote for Laboratory Evaluations 
at screening  (Table 7 ).  Added urinalysis to screening procedures 
text (Section 12.1 ).  Removed the reference to only clinically 
significant abnormal lab findings will be recorded as Advers e Events 
because ALL abnormal laboratory findings will be recorded and then clinical significance will be decided (Section 13.1 ).  Various 
new Adverse Event and other reporting criteria updated per new 
company standards (Sectio n 13 ) including addition of an AESI 
section (Section 1.1.1). an SAE exception (Section 13.2 ), SEA 
reporting to Tesaro (Sections 13.2.1  and 1.1.1 ), a pregnancy section 
(Section 13.3.2.1), Special Situations (Section 1.1.1), and Reporting 
Product Complaints (Section 1.1.1 ).  Remove d Karen Allen and 
Gordana Vlahovic from Sub- Investigators.  Added Margaret 
Johnson to sub -investigators.  Changed Lead Study Coordinator to 
Edy Parker and Lead Regulatory Coordinator to Jennifer Jackman.  Some minor administrative edits.  
Changed Lead Regul atory Coordinator to Deborah Iden.  Updated all 
references of Tesaro to TerSera, the new sponsor. Exclusion criteria #1 removed and combined with #2 to indicate that co -medication 
interaction with rolapitant will be reviewed by the pharmacist for eligibilit y and added exclusion criteria for contraindicated 
medications (Section s 5.4 and 11.2 ). Added a sentence after 
exclusion criterion 18 that says to refer to a study Me mo to File for 
exceptions to the exclusion criteria. (Sections 5.4 and 11.2)  
Reordered the Inclusion and Exclusion criteria numbering  to better 
lend itself to how the questions are reviewed when screening by 
the CRC.  Removed collection of every 2 week s tandard of care 
blood draw at the request of the PI who determined it was unnecessary to collect the data ( Table 7
) and throughout the 
protocol . Section 13 , Safety Monitoring and Reporting, was 
significantly revise d to both include language sugge sted by the new 
sponsor TerSera  and to remove  sectio ns that had only been 
included based on the previous sponsor’s requirements . Corrected 
inconsistencies in the language related to screening time points. 
Removed overall dur ation of study. Other minor administrative 
changes.  
 Date 2/18/2022  The accrual target for this study is reduced to 57 patients.  The 
decision to terminate early has not been influenced by the data collected to date, as no interim analyses have been condu cted.  The 
analyses as described below will be conducted; however, they may 
no longer have the power to detect the hypothesized effect size  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 2  of 52 
CONFIDENTIAL 
 1 TABLE OF CONTENTS  
2 LIST OF FIGURES  ................................................................................................................ 6 
3 LIST OF TABLES  .................................................................................................................. 6 
4 LIST OF ABBREVIATIONS  ................................................................................................. 7 
5 PROTOCOL SYNOPSIS AND RESEARCH SUMMARY  .................................................. 8 
5.1 Purpose  ............................................................................................................................. 8 
5.2 Background and Significance  ........................................................................................... 8 
5.3 Design and Procedure  ....................................................................................................... 9 
5.4 Selection of Subjects  ...................................................................................................... 10 
5.5 Subject Recruitment and Compensation ........................................................................ 12 
5.6 Consent Process  .............................................................................................................. 12 
5.7 Subject’s Capacity to Give Legally Effective Consent  .................................................. 13 
5.8 Risk/Benefit Assessment  ................................................................................................ 13 
5.9 Costs to the Subject  ........................................................................................................ 14 
5.10  Duration of Study ....................................................................................................... 14 
5.11  Data Analysis and Statistical Consid erations  ............................................................. 14 
6 STUDY SCHEMA ................................................................................................................ 15 
7 BACKGROUND AND SIGNIFICANCE  ............................................................................ 16 
7.1 Study Disease ................................................................................................................. 16 
7.2 Study Agent  .................................................................................................................... 16 
7.2.1  Pre-clinical experience (as noted in the Rolapitant Investigator’s brochure)  ......... 20 
7.2.2  Clinical experience (as noted in the Rolapitant Investigator’s brochure and the 
package insert)  ...................................................................................................................... 20 
7.3 Study Purpose/Rationale  ................................................................................................ 28 
8 OBJECTIVES AND ENDPOINTS  ...................................................................................... 30 
9 INVESTIGATIONAL PLAN  ............................................................................................... 31 
9.1 Study Design .................................................................................................................. 31 
9.2 Standard of Care Chemotherapy Treatment Plan  ........................................................... 31 
9.3 Standard of Care Radiation Treatment Plan  ................................................................... 32 
9.3.1  Dose Definition and Schedule  ................................................................................ 32 
9.3.2  Physical Factors  ...................................................................................................... 32 
9.3.3  Localization, Simulation, and Immobilization  ........................................................ 32 
9.3.4  Treatment Planning and Safety ............................................................................... 32 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 3  of 52 
CONFIDENTIAL 
 9.3.5  Dose Limitations to Critical Structures  ................................................................... 33 
9.3.6  Safety Considerations  ............................................................................................. 33 
9.4 Anti-emetic Treatment  ................................................................................................... 33 
9.4.1  Antiemetic Treatment Plan  ..................................................................................... 33 
9.4.2  Missed Doses .......................................................................................................... 33 
9.4.3  Concomitant Medications ....................................................................................... 33 
9.5 Study Drug Blinding  ...................................................................................................... 34 
9.6 Randomization ............................................................................................................... 34 
9.7 Rationale for Selection of Dose, Regimen, and Treatment Duration  ............................. 34 
9.8 Definition of Evaluable Subjects, On Study, and End of Study .................................... 34 
9.9 Early Study Termination  ................................................................................................ 34 
10 STUDY DRUG  ..................................................................................................................... 34 
10.1  Names, Classification, and Mechanism of Action  ..................................................... 34 
10.2  Packaging and Labeling .............................................................................................. 35 
10.3  Supply, Receipt, and Storage  ...................................................................................... 35 
10.4  Dispensing and Preparation ........................................................................................ 35 
10.5  Compliance and Accountability  ................................................................................. 35 
10.6  Disposal and Destruction  ............................................................................................ 35 
10.7  Other Study Drugs (Ondansetron)  .............................................................................. 35 
10.7.1  Description  .............................................................................................................. 35 
10.7.2  Source  ..................................................................................................................... 35 
10.7.3  Dosage and Administration..................................................................................... 35 
10.7.4  Drug Ordering ......................................................................................................... 35 
11 SUBJECT ELIGIBILITY  ..................................................................................................... 36 
11.1  Inclusion Criteria  ........................................................................................................ 36 
11.2  Exclusion Crit eria ....................................................................................................... 36 
12 SCREENING AND ON -STUDY TESTS AND PROCEDURES ........................................ 36 
12.1  Screening Examination ............................................................................................... 37 
12.2  Treatment Period  ........................................................................................................ 37 
12.3  End of Treatment  ........................................................................................................ 38 
12.4  Follow -up Period  ........................................................................................................ 38 
12.5  End of Study ............................................................................................................... 38 
12.6  Early Withdrawal of Subject(s)  .................................................................................. 38 
12.6.1  Criteria for Early Withdrawal  ................................................................................. 38 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 4  of 52 
CONFIDENTIAL 
 12.6.2  Follow -up Requirements for Early Withdrawal  ..................................................... 38 
12.6.3  Replacement of Early Withdrawal(s)  ...................................................................... 39 
12.7  Study Assessments  ..................................................................................................... 39 
12.7.1  Medical History  ...................................................................................................... 39 
12.7.2  Physical Exam  ......................................................................................................... 39 
12.7.3  MASCC Antiemesis Tool (MAT)  .......................................................................... 39 
12.7.4  Treatment Satisfaction Questionnaire for Medication (TSMQ -9) .......................... 39 
13 SAFETY MONITORING AND REPORTING  .................................................................... 40 
13.1  Adverse Events  ........................................................................................................... 40 
13.1.1  Reporting of AEs  .................................................................................................... 40 
13.2  Serious Adverse Events  .............................................................................................. 40 
13.2.1  Reporting of SAEs  .................................................................................................. 41 
13.2.2  Reporting Product Complaints for TerSera Products  ............................................. 41 
13.3  Special Warnings and Precautions  ............................................................................. 41 
13.4  Safety Oversight Committee (SOC)  ........................................................................... 41 
14 QUALITY CONTROL AND QUALITY ASSURANCE  .................................................... 42 
14.1  Monitoring  .................................................................................................................. 42 
14.2  Audits .......................................................................................................................... 42 
14.3  Data Management and Processing  .............................................................................. 43 
14.3.1  Case Report Forms (CRFs)  ..................................................................................... 43 
14.3.2  Data Management Procedures and Data Verification  ............................................. 43 
14.3.3  Study Closure  .......................................................................................................... 43 
15 STATISTICAL METHODS AND DATA ANALYSIS  ...................................................... 43 
15.1  Analysis Sets .............................................................................................................. 43 
15.2  Patient Demographics and Other Baseline Characteristics  ........................................ 43 
15.3  Treatments .................................................................................................................. 44 
15.4  Primary Objective  ....................................................................................................... 44 
15.4.1  Variable  ................................................................................................................... 44 
15.4.2  Statistical Hypothesis, Model, and Method of Analysis  ......................................... 44 
15.5  Secondary Objectives  ................................................................................................. 44 
15.5.1  Key Secondary Objective  ....................................................................................... 45 
15.5.2  Other Secondary Objectives  ................................................................................... 45 
15.6  Interim Analysis  ......................................................................................................... 46 
15.7  Sample Size Calculation  ............................................................................................. 46 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 5  of 52 
CONFIDENTIAL 
 15.7.1  Original Study Design ............................................................................................. 46 
15.7.2  Modified Study Design ........................................................................................... 47 
16 ADMINISTRATIVE AND ETHICAL CONSIDERATIONS  ............................................. 47 
16.1  Regulatory and Ethical Compliance  ........................................................................... 47 
16.2  DUHS Institutional Review Board and DCI Cancer Protocol Committee  ................. 48 
16.3  Informed Consent  ....................................................................................................... 48 
16.4  Study Documentation ................................................................................................. 48 
16.5  Privacy, Confidentiality, and Data Storage  ................................................................ 49 
16.6  Data and Safety Monitoring ....................................................................................... 49 
16.7  Protocol Amendments  ................................................................................................ 49 
16.8  Records Retention ....................................................................................................... 49 
17 REFERENCES ..................................................................................................................... 50 
18 APPENDICES ...................................................................................................................... 51 
18.1  Appendix 1: Se quence A -TSQM9/MAT Questionnaire  ............................................ 51 
18.2  Appendix 2: Sequence B -TSQM9/MAT Questionnaire  ............................................ 51 
18.3  Appendix 3: Medication Log:   Sequence  A .............................................................. 51 
18.4  Appendix 4: Medication Log:   Sequence B  ............................................................... 51 
18.5  Appendix 5: Birth Control Recommendations  ........................................................... 51 
 
  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 6  of 52 
CONFIDENTIAL 
 2 LIST OF FIGURES  
Figure 1: No Emesis an d No Nau sea Interfering with Daily Life over Cycles 2-6 ....................... 27 
 
3 LIST OF TABLES  
Table 1: The study of drug, Varubi® (rolapitant) with MEC can cause the following effects: ... 13 
Table 2: Effects of Rolapitant on the Pharmacokinetics of Co-administered Drugs* ................ 19 
Table 3:  Complete Response  by CINV Phase  and Study ............................................................. 24 
Table 4:  Treatment Regimens in Studies 1 a nd 2 ........................................................................ 25 
Table 5: T reatment Regimens in Study 3 .................................................................................... 26 
Table 6:  Percen t of Patients Receiving Emetogenic Chemotherapy Responding by Treatment 
Group for the HEC Studies 1 a nd 2 and for the MEC Study 3 ..................................................... 26 
Table 7: Screening and Study -related Tests and Procedures  ..................................................... 37 
 
                        
    
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 7  of 52 
CONFIDENTIAL 
 4 LIST OF ABBREVIATIONS  
5HT 3-RA        5 -hydr oxytryptamine receptor antagonist  
AE Adverse Event  
AESI  Adverse Event of Special Interest  
ALT Alanine Aminotransferase  
ALC Absolute Lymphocyte Count  
ASCO              American Society of Clinical Oncology  
AST Aspartate Aminotransferase  
BUN  Blood Urea Nitr ogen  
CBC Complete Blood Count  
CMP  Comprehensive Metabolic Panel 
CR Complete Response  
CT Computed Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
DLT Dose Limiting Toxicity  
DSMB  Data and Safety Monitoring Board  
ECOG  Eastern Cooperative Oncol ogy Group 
H&P  History & Physical Exam  
HEC                 Highly emetic chemotherapy  
HRPP Human Research Protections Program  
IV (or iv)  Intravenously  
MASCC           Multinational Association of Supportive Care in Cancer  
MAT                MASCC Antiemesis Tool      
MEC                Moderately emetic chemotherapy  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute  
NCCN             National Comprehensive Caner Network  
NK 1-RA           Neurokinin -1 receptor antagonist  
ORR Overall Response Rate  
OS Overal l Survival  
PBMCs  Peripheral Blood Mononuclear Cells 
PET                 Positron Emission Tomography  
PD Progressive Disease  
PFS Progression Free Survival 
PRTBTC          Preston Robert Tisch Brain Tumor Center  
p.o. per os/by mouth/orally  
RT                   Radiation Therapy  
RINV               Radiation Induced Nausea and Vomiting  
PR Partial Response  
SAE Serious Adverse Event  
SD Stable Disease  
SGOT  Serum Glutamic Oxaloacetic Transaminase  
SPGT Serum Glutamic Pyruvic Transaminase  
TSQM -9         Treatment Satisfaction Questionnaire for Medication  
WBC  White Blood Cells  
  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 8  of 52 
CONFIDENTIAL 
 5 PROTOCOL  SYNOPSIS AND RESEARCH SUMMARY  
5.1 Purpose  
The purpose of this two-arm randomized phase 2  study is to assess the efficacy and patient satisfaction of oral 
rolapitant plus ondansetron vs. oral ondansetron monotherapy  in malignant glioma (MG) patients receiving six 
weeks of standard cranial radiation therapy (RT) and concomitant temozolomide (TMZ).  
       
Primary Objective:  
1. Compare the efficacy of rolapitant plus ondansetron vs. ondansetron mono therapy in the prevention 
of chemo radiation -induced nausea and vomiting ( chemo -RINV), as measured by the overall complete 
response (CR) rate ( where CR is defined as no emesis, no rescue antiemetic), among malignant glioma 
patients during the standard ~ 6 weeks of RT and concomitant multi -dose TMZ  
 
Secondary Objectives:  
1. KEY secondary objective: Assess whether malignant glioma patients receiving RT and concomitant TMZ 
are more satisfied with rolapitant plus ondansetron vs. ondansetron monotherapy for the prevention of 
chemo -RINV  
2. Describe the rationale behind a patient’s satisfaction with antiemetic preference base d upon 
effectiveness, convenience and global satisfaction  
3. Compare the efficacy of rolapitant plus ondansetron vs. ondansetron monotherapy  in the  prevention of 
nausea and vomiting  separately , as measured by the respective CIN, CIV - CR rates, among malignant 
glioma patients during RT and concomitant TMZ  
4. Evaluate compliance of rolapitant plus ondansetron vs. ondansetron  monotherapy  
5. Assess the safety of rolapitant plus ondansetron vs. ondansetron monotherapy in the prevention of 
RINV in glioma patients receiving RT and concomitant TMZ  
 Hypotheses  
1. This is a hypothesis- testing protocol. Hypothesis: rolapitant plus ondansetron will produce an equally or 
a more effective RINV CR rate when compared to ondansetron  monotherapy in glioma patients 
receiving RT and concomitant TMZ.  
5.2 Background and Significance   
Radiation -induced nausea and vomiting (RINV) is a clinically distressing symptom in patients undergoing 
radiotherapy. The RINV risk in patients receiving cranial/cranio spinal radiation without concurrent 
chemotherapy is estimated to be around 30 -60%.1 Although there is limited evidence to suggest t hat the RINV 
incidence is higher with the addition of temozolomide to RT than without, one would only predict that the 
incidence of RINV without emetic prophylaxis among patients treated with combination therapy (i.e. radiation 
and concurrent temozolomide) is higher . In tw o recent clinical studies, 35% or more of cranial RT patients 
experienced RINV.2,3 The risk of RINV increases when concomitant chemotherapy with TMZ is added to brain 
RT,4 as TMZ is moderately emetogenic.5,6 Temozolomide prescribing information reports nausea and vomiting 
rates of 36% and 20% respectively for concomitant RT+TMZ and concomitant RT+TMZ with standard 
antiemetic treatment.7 Comparable rates of nausea (35%) and vomiting (26%)  were reported in a recent study 
of Korean MG patients receiving such treatment.8 The National Comprehensive Cancer Network (NCCN), 
Multinational Association of Supportive Care in Cancer (MASCC), and American Socie ty of Clinical Oncology 
(ASCO) publish current clinical practice guidelines addressing the issue of RINV  9,10,6 and t hese guidelines 
recommend that patients receiving concomitant chemotherapy and RT treatment should be given antiemetic 
prophylaxis according to the emetogenicity of the chemotherapy prescribed, unless the emetic risk of the 
radiotherapy is higher. Given the moderate emetogenicity of TMZ therapy, patients with brain tumors are 
classified as a moderate -risk group for RINV.  
 
At Duke PRTBTC , we estimate the RINV rate to be approximately 50% without the use of ondansetron . Despite 
prophylaxis against nausea and vomiting during cranial RT and concomitant temozolomide therapy, Stupp 4,11 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 9  of 52 
CONFIDENTIAL 
 reported a  threefold (14% - 40/287) increase in the grade 2- 4 nausea/v omiting rate compared to a 4% 
(11/286) nausea/vomiting rate with radiotherapy alone. Without prophylaxis, up to 60% of patients r eceiving 
cranial radiation may experience acute nausea and vomiting, which can lead to various adverse effects 
including dehydration, electrolyte imbalance, malnutrition, and aspiration pneumonia. These complications 
can further delay/decrease the therapeu tic effect of temozolomide and radiation treatment, ultimately 
leading to lower response rates and decreased health -related quality of life (HRQoL).  
 
We conducted the first phase 2 single arm trial of palonosetron (PAL), a long acting 5 -hydroxytryptamine (5-
HT 3) receptor antagonist (5HT 3-RA), for the prevention of RINV in primary MG su bjects receiving RT (54- 60 Gy) 
and concomitant multi -dose, daily TMZ (75 mg/m2) +/- bevacizumab.  Results from this study demonstrate 
that a 5HT 3-RA, such as PAL or ondansetr on, can be safe and effective , however based on the results, there is 
still room for improvement of anti -emetic response related to CR rates and HRQoL, which could be addressed 
by combining a 5- HT 3-RA and NK -1-RA12. PAL was safe and effective; however, there is room for improvement 
in the CR rates and HRQoL , which may be achieved with rolapitant plus ondansetron, a potentially more 
effective combination anti -emetic regimen.  The most studied agents in the RINV settin gs are the 5HT 3-RAs, 
with overall moderate response and low toxicity. However, agents such as the tachykinin NK -1 receptor 
antagonist may play a role in improving response rates,  but there need s to be further studie s in randomized 
controlled trials.13 
 
Rolapitant, an FDA- approved , long -acting , highly selective NK 1 receptor antagonist (RA), in combination with a 
5-HT 3 RA (ondansetron , granisetron ) and dexamethasone is a well- tolerated antiemetic combination that has 
demonstrated superiority for the prevention of highly -emetic chemotherapy induced nausea and vomiting 
(CINV)14. In a global, randomized, double -blind, active -controlled, phase 3 multi -center study, 1369 patient s 
receiving moderately -emetic chemotherapy or regimens containing an anthracycline and cyclophosphamide 
were randomly allocated (after stratification by sex) to receive either one 180 mg dose of oral rolapitant or a 
placebo (active control) 1 -2 hours  befor e administration of chemotherapy. All patients also received 
granisetron (2 mg orally)  on days 2 -3 and dexame thasone (20 mg orally) on day 115, on cycles of  a minimum of 
14 days. The primary efficacy end point was c omplete response (CR indicated by  no emesis or rescue 
medication) during the delayed (>24- 120 h ours) phase.  A significantly larger proportion of patients receiving 
rolapitant had complete responses in the delayed phase than did those receiving active cont rol (475 [71%] vs 
410 [62%]; odds ratio 1.6, 95% CI 1.2- 2.0; p=0.0002).15 Toxicities were similar in the rolapitant and control 
groups, with the most frequently reported treatment- related treatment -emergent adverse events being 
fatigue, constipation, and headache.15 No serious adverse event was treatment -related, and no treatment -
related adverse event resulted in death.15 
 
The oral c ombination of rolapitant plus ondansetron has not been stu died in the prevention of RINV in 
patients receiving RT and multi -dose  chemotherapy for MG . Additional advantages to using rolapitant plus 
ondansetron in the setting of radiation with concurrent mul ti-dose oral chemotherapy are that it avoids side 
effects associated with intravenous administration (e.g. palonosetron) and eliminates treatment room costs. 
Furthermore, rolapitant, as opposed to the aprepitant or netupitant, is not a CYP3A4 inhibitor or inducer of 
common drugs used in glioma patients (e.g. dexamethasone , enzyme -inducing anticonvulsants , or irinotecan) 
thus reducing drug- induced side effects. Ultimately, rolapitant plus ondansetron may improve overall 
effic acy (CR rates), cost, HRQoL and patient satisfaction.  
5.3 Design and Procedure 
This proposed study is a  randomized  phase 2 trial of rolapitant plus ondansetron vs. ondansetron 
monotherapy  for the prevention of chemo -RINV in primary malignant glioma subjects receiving radiation 
therapy (RT) and concomitant multi -dose temozolomide (TMZ).  All eligible subjects should receive a planned 
total dose of 5 4-60 Gy of radiation and 75 mg/m2 of temozolomide daily for a total of six weeks. Glioma 
patients will be randomized in an unblinded fashion to rece ive one of two treatment sequences of antiemetic 
therapy for the prevention of nausea and vomiting associated with RT and concomitant TMZ.  
 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 10 of 52 
CONFIDENTIAL 
 Sequence A involves administration of ondansetron alone  for 3 weeks followed by the use of rolapitant X 1 
dose plus  daily ondansetron for 3 weeks; whereas , sequence B involves the use of rolapitant X 1 dose plus 
daily ondansetron for 3 weeks followed by 3 weeks of daily ondansetron alone.   For the rolapitant plus 
ondansetron weeks (1 or 4), patients will self -administe r the oral rolapitant pill 1-2 hours before the first 
fraction of radiation on the plan ned week (see schema). Subjects will be given a prescription for ondansetron 
8 mg pills to be taken 30 minutes before their TMZ dose.  After the start of radiation thera py, the type of 
additional rescue antiemetic medication , if needed,  will be left up to the investigator’s discretion.  Subjects 
will be informed  that they are allowed to take rescue antiemetic medication while participating in either arm  
of the  study .  If the subject experiences nausea and vomiting and does take a rescue antiemetic, the subject 
will be asked to record the use of additional antiemetic  in a medication log provided to them . Subjects will 
complete weekly med ication log s and surveys (see Appendices ) to capture study outcomes. Subjects will be 
told that the study is voluntary and that they may exit at any time if they wish.  
 
Approximately 170 patients will provide informed consent in order for 160 patients to be randomized to either 
treatment sequence A or B. The 170 estimate is to al low for screen failures and dropout rates. All subjects 
must give written informed consent to participate in the study. Patients will be screened - 28 to 0  days prior to 
the start of the study. During this time period the following information will be recorded: physical 
examination; vital signs and weight; laboratory studies (complete blood count with differential, blood 
chemistries, liver function tests and urinalysis): medical history; c oncomitant medications (steroids and 
anticonvulsants) and predictors of RINV (irradiation site, planned dose treatment field, alcohol intake, gender, 
age etc.).  Laboratory evaluations, performance status, concomitant medications, and adverse events for fin al 
eligibility should be confirmed within 2 weeks of initiating radiation with concomitant TMZ  
 
Patients will obtain stand ard of care blood work (per local oncologistduring treatment  complete blood count 
with differential, blood chemistries, liver function  tests ). Toxicity will be assessed based on the Common 
Toxicity Criterion (CTC version 4). The patient will be asked to complete the MASCC nausea and vomiting 
questionnaire on day 0 (baseline), and days 1, 2, 4, and 7 (for days 7, 1, 2-3, and 4-6, respecti vely) of each 
week of radiation therapy.    
 
At the end of weeks 3 & 6, the subject will be asked to fill out a Treatment Satisfaction Questionnaire for 
Medication (TSQM -9, Section 18.1 and 18.2) and will be asked at the end of week 6 to choose which 
antiemetic they prefer. 
5.4 Selection of Subjects  
Selection of Subjects: Patients with a malig nant glioma who plan to undergo standard RT with concomitant 
daily temozolomide (TMZ) therapy  
 
Inclusion Criteria:  
1. Patients must have histologically -confirmed , newly -diagnosed malignant glioma (glioblastoma, 
gliosarcoma, anaplastic astrocytoma, anaplastic  oligoastr ocytoma, anaplastic pleomorphic 
xanthoastrocytoma, or anaplastic oligodendroglioma) and are scheduled to receive radiotherapy (for a 
total of 54-60 Gy ) and concomitant daily temozolomide therapy (at a dose of 75 mg/m2 for one complete 
6-week cycle).  
2. Age ≥ 18 years  
3. Karnofsky ≥ 60%  or ECOG 0 -2 
4. For patients on higher than physiological level of corticosteroids, they must have been on a stable dose 
for 1 week prior to initiating study drug, and the dose  should not be escalated over entry dose level, i f 
clinically possible  
5. Ability and willingness to give informed consent  
6. Female patients of childbearing potential must have a negative pregnancy test at Screening  
7. Female patients of childbearing potential must agree to use an acceptable method of birth cont rol (please 
refer to the attached document, Birth Control Recommendations (Appendix 18.5)) from the signing of 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 11 of 52 
CONFIDENTIAL 
 informed consent form  and to continue its use during the study and for at least 90  days after the final 
dose  
8. Male patients must agree to use an acceptable form of birth control (please refer to the attached 
document, Birth Control Recommendations (Appendix 18.5) from study Day 1 through at least 9 0 days 
after the final dose  
9. Hematocrit > 29%, ANC  >1,000 cells/mm3, platelets >100,000 cells/ mm3 
10. Serum creatinine <1.4 mg/dl, bilirubin <1.5 times upper limit of normal  
11. Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal range (ULN).  For subjects with known liver 
metastases ≤5 x ULN, and alanine aminotransferase (ALT) ≤2.5 x ULN.  For subjects wi th known liver 
metastases ≤5 x ULN  
 
 Exclusion Criteria: 1. Co-medications that may interact with rolapitant as reviewed by Duke Preston Robert Tisch Brain Tumor 
investigator pharmacist  
2. Co-medications that are contraindicated in patients on rolapitant includ ing pimozide, thioridazine, 
carbamazepine, colchicine, dabigatran (Pradaxa), edoxaban (Savaysa), fosphenytoin, metoprolol, phenobarbital, phenytoin, primidone, and warfarin 
3. Inability or unwillingness to cooperate with the study procedures  
4. Prophylactic medi cation for the  prevention  of nausea and vomiting 24 hours  prior to the start of radiation 
therapy through the full course of radiation therapy is prohibited, with the exception of the study drug. Corticosteroids will be allowed for treatment of cerebral sw elling  
5. Ongoing vomiting from any organic etiology  
6. Previous participation in any clinical trial involving rolapitant     
7. Received rolapitant within 21 days prior to study enrollment  
8. Prior cancer chemotherapy or radiotherapy  
9. Any current treatment, medical history, or uncontrolled condition, other than malignancy, (e.g., 
alcoholism or signs of alcohol abuse, seizure disorder, medical or psychiatric condition) that, in the 
opinion of the investigator, would confound the results of the study or pose any unwarran ted risk in 
administering study drug to the subject  
10. Patient has a known hypersensitivity to the administration of rolapitant or its excipients  
11. Patient has a history of severe renal or hepatic impairment, severe bone marrow suppression, or systemic infect ion  
12. Patient is a woman with a positive serum pregnancy test at Screening, is pregnant, breast -feeding, or is 
planning to conceive children within the projected duration of the study treatment  
13. Patient has taken the following agents within the last 48 hours  prior to the start of treatment with study 
drug:  
• 5-HT 3 antagonists (ondansetron, granisetron, dolasetron, tropisetron, etc.).  
• Benzamides (metoclopramide, alizapride, etc.)  
• Domperidone  
• Cannabinoids  
• NK1 antagonist (aprepitant)  
• Benzodiazepines (lorazepam, alprazolam, etc.)  
• herbal medications or preparations in doses designed to ameliorate nausea or emesis  
14. Patient has taken phenothiazines (prochlorperazine, fluphenazine, perphenazine, thiethylperazine, chlorpromazine, etc.) for any indication within the  last 48 hours prior to the start of treatment with study 
drug  
15. Palonosetron is not permitted within 7 days prior to administration of investigational product  
16.  Any vomiting, retching, dry heaves, or clinically significant nausea (i.e., NCI Common Toxicity Criteria 
version 4.0 grade 2 -4 nausea) caused by any etiology in the 24 hrs. preceding day 1 of the study 
intervention  (ondansetron or ondansetron with rolapitant ) as scheduled to begin on day 1 of radiation 
and chemotherapy. Or a patient who has a history of anticipatory nausea and vomiting .  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 12 of 52 
CONFIDENTIAL 
 17. Patient must not have been dosed with test drug or blinded study drug in another investigational study 
within 30 days or 5 half -lives of the biologic activity of the test drug, whichever is longer, before the time 
of first study dose  
18. Patient who is receiving investigational agent(s) as part of another  clinical study at the time of screening 
or who anticipates receiving investigational agent(s) during their scheduled radiotherapy and concomitant daily temozolomide thera py. (Please refer to study Memo to File regarding exceptions to this exclusion 
criteria)   
 
5.5 Subject Recruitment and Compensation  
Subjects will be recruited for this study as follows:   
Subjects will be identified from patients referred to the Preston Robert  Tisch Brain Tumor Center Clinic. Upon 
determination that a subject’s tumor histology and radiographic findings are compatible with the eligibility criteria for this study protocol, the study will be briefly explained to the subject by the clinical researc h 
coordinator (CRC) or Mary Lou Affronti DNP, RN, MSN, ANP, MHSc, or Dr. Katherine Peters , the principal 
investigators (PIs) , or a member of the research team in the PRTBTC (may include RNs, CRCs, MDs or advanced 
practice providers).  If the subject indica tes interest in study participation, study education sheets will be 
provided by the research nurse clinicians as this provides the most comprehensive explanation of the study in lay terms. If the patient shows continued interest, the PI or member of the re search study staff will thoroughly 
explain the required elements of informed consent and all aspects of the study to the subject including but not limited to inclusion/exclusion criteria, risks, benefits, and alternatives to study participation. If the pat ient 
desires additional time to consider participation in the study, the study staff will send the patient home with the consent form. If the patient takes the consent form  home  and decides to participate , a return 
appointment to the PRTBTC will be schedul ed with the study nurse and study coordinator to complete the 
informed consent process face to face with the patient . 
 
No compensation for participation will be given to subjects.  The study medication, rolapitant , is FDA -
approved and will be provided at no charge by the study supporter , TerSera .  A third party insurance carrier 
will be responsible for the cost of clinic visits, laboratory tests, dexamethasone, and routine care and 
treatment for the brain tumor (including ondansetron and rescue medication).   How much subjects will have 
to pay, depends on whether or not they have insurance or what costs  the insurance will cover. Insurance 
coverage cannot be guaranteed for all tests and treatment s related to this study. Treatment to help control 
side effects m ay also result in added costs.   
5.6 Consent Process  
Subjects must give informed consent according to institutional review board (IRB) guidelines prior to 
registration.  The subject will receive a copy of the signed consent document. The original signed consent 
document will be retained by the PRTBTC in a study binder. The PI or designee will fully explain the purpose 
and potential risks and benefits of the study to the subject prior to enrollment and address any questions 
posed by the subject. In addition, the  PI or designee will explain to each subject the nature of the study, its 
purpose, the procedures involved, the expected duration, the potential risks and benefits involved and any additional discomfort that may be anticipated from taking this antiemetic d rug combination . Each subject will 
be informed that participation in the study is voluntary and that he/she may withdraw from the study at any 
time and that withdrawal of consent will not affect his/her subsequent medical treatment or relationship with 
the treating physician.   
 
The prospective participant will have as much time as he/she may need to make an informed decision about 
the study, and all treatment- related questions will be answered.   Prospective participants will be consented in 
an exam room wh ere only the research staff, the patient,  and his/her family  (if desired)  are present.  Before, 
during, and after the consent process, the research team and investigators will be available in person and by 
phone to answer any questions the participants may  have.  Any and all other available treatment options are 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 13 of 52 
CONFIDENTIAL 
 offered to the patient in order to avoid undue influence.  Participants are not offered compensation for this 
study , in order to avoid any monetary coercion/influence.  
 For those prospective partici pants who cannot read or are blind, the consent document will be read out loud 
verbatim to the participant, who is encouraged to have a caregiver or family member present  as a witness 
who can read along as the consent form is read.  If the prospective part icipant cannot read or understand 
English, an approved, translated, short form consent document will be provided to the participant.  A translator  and a translator/witness , along with the Brain Tumor Center attending physician, nurse, or 
coordinator, will review the short form consent document and the full English version of the consent and all 
relevant study documents with the subject.  If a subject has a physical impairment that limits their ability to 
provide a signature, an impartial witness will be utilized as part of the informed consent process. This impartial 
witness will date and sign the Informed Consent along with the person obtaining the informed consent.   
5.7 Subject’s Capacity to Give Legally Effective Consent  
Subjects participating in this study are competent to sign informed consent, based upon inclusion criteria and 
investigator assessment . Subjects who do not have the capacity to give legally effective consent will not be 
enrolled. 
5.8 Risk/Benefit Assessment 
The natural progression of this type of brain tumor and standard treatment modalities are associated with 
potentially life -threatening complications and side effects.  The antiemetic study drug (rolapitant ) may 
increase the risk of side effects.  
Table 1: The study of dr ug, Varubi® (rolapitant) with MEC can cause the following effects:  
 VARU BI Regimen 
(VARU BI, Dexamethasone, and 5-HT3 
Recep tor Antagonist) 
N = 670 Control 
(Placebo, Dexamethasone, and 
5-HT3 Rece ptor Antagonist) 
N = 674 
Decr eased appetite  9% 7% 
Dizzi ness 6% 4% 
Dyspepsia 4% 2% 
Urinary tract infection 4% 3% 
Stomatitis 4% 2% 
 Allergic reactions may occur rarely.  Hives; tightness of the throat; difficulty breathing or s wallowing; 
hoarseness should be reported to the study doctor immediately.  
 Note:  The Reference Safety Information for the study will be the United States Package Insert (USPI).  
 
Ondansetron  
Most common side effects (occurring in 9 to 24% of subjects):  
• Headache  
• Fatigue  
• Constipation  
 
Side effects occurring in 5 -6% of subjects:  
• Diarrhea  
• Dizzine ss 
 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 14 of 52 
CONFIDENTIAL 
 Other side effects that have been reported by people who have taken ondansetron (intravenous  
[by vein] or by mouth) in clinical studies include the following:  
• Low oxygen level in the blood (Hypoxia)  
• Fever  
• Slow heart rate (Bradycardia)  
• Urinary retentio n 
• Itching  
• Drowsiness/sedation  
• Shivers  
 
Serotonin syndrome has been reported when ondansetron has been taken at the same time as another  
medication that affects serotonin, a type of neurotransmitter (a chemical produced by the body). Such  
medications inclu de certain types of anti -depressants and migraine medications. The study team will 
review your list of medications with you to find out if you are taking any of these medications. Please  
seek immediate medical attention if you experience any of the followi ng symptoms of serotonin  
syndrome: changes in mental status, autonomic instability (this could include fainting or dizziness,  
exercise intolerance, sweating too much or too little, difficulty with urinating, sexual problems, and  
visual problems), neuro -mus cular symptoms, and gastrointestinal symptoms, such as loss of appetite,  
bloating, diarrhea, constipation, or difficulty swallowing.  
 
Other medications:  
Subjects should tell the study doctor about all drugs that they have been taking recently and are takin g while 
enrolled in this study. Also, if a severe side effect occurs, the study doctor may permanently stop the study 
drug. Subjects must tell their study doctor and research staff of their concern of any of these side effects, as 
listed above.  
5.9 Costs to t he Subject  
The study drug, rolapitant, is FDA -approved and will be provided at no charge. Ondansetron is commercially 
available and will not be covered by the study. The subject or their third party insurance carrier will be 
responsible for the cost of his /her clinic visits, laboratory tests, dexamethasone (as needed), and the routine 
care and treatment of their brain tumor, e.g. the radiation therapy and temozolomide.  How much one will 
have to pay, depends on whether or not the subject has insurance and t hose costs that his/her insurance will 
cover. Insurance coverage cannot be guaranteed for all tests and treatments related to this study. Treatment 
to help control any side effects that may occur may also result in added costs to the subject or their insur ance 
company. Subjects will not be paid for taking part in this study.  
5.10 Duration of Study  
 Participants will be in the study for 8 weeks which includes ~6 weeks of treatment and 2 weeks of monitoring 
for adverse events following the end of radiation and con current temozolomide treatment.  
5.11 Data Analysis and Statistical Considerations  
One hundred seventy (170) glioma patients will be enrolled with the expectation that 160 patients will be 
randomized  (unblinded)  to receive one of two treatment sequences of anti -emetic therapy for the prevention 
of nausea and vomiting associated with RT and concomitant TMZ. Sequence A involves a 3- week regimen of 
daily ondansetron followed by a 3- week regimen  consisting of rolapitant (day 22  only) and daily ondansetron; 
whereas , Sequence B involves a 3- week regimen of rolapitant (day 1 only) and daily ondansetron followed by a 
3-week regimen of daily ondansetron.    
 
The primary endpoint of this study is  CR rate.  Though the primary CR rate endpoint will focus on treatment 
during t he first 2 weeks of RT and TMZ, a cross -over design is proposed so that a patient will experience both 
modes of treatment, and be equipped to make a comparative assessment of preference , which is a key 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 15 of 52 
CONFIDENTIAL 
 secondary outcome .  An interim analysis (as described in 15.6)  will be conducted by the study statistician or 
designee  after 40 patients are accrued to each sequence.  
 
We expect that 152 of the 160 randomized patients to provid e an assessment of their experience during the 
first 2 weeks of treatment with the first regimen.  With 152 patients, there is 80% power to detect an increase in the CR rate from 75% with ondansetron to 90% with the combination of ondansetron and rolapitant 
(α=0.05; one -tailed)  with a chi -square test . 
6 STUDY SCHEMA  
 
 
 
  

Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 16 of 52 
CONFIDENTIAL 
 7 BACKGROUND AND SIGNIFICANCE  
7.1 Study Disease  
Radiation -induced nausea and vomiting (RINV) is a clinically distressing symptom in patients undergoing 
radiotherapy. The RINV risk in patients rece iving cranial/craniospinal radiation without concurrent 
chemotherapy is estimated to around 30 -60%.1 Although there is limited evidence to suggest what the RINV 
incidence is higher with the addition of temozolomide  to RT than without, one would only predict that the 
addition of concurrent chemotherapy with brain irradiation would only increase the RINV rate.   In two recent 
clinical studies, 35% or more of cranial RT patients experienced RINV.2,3 The risk of RINV increases when 
concomitant chemotherapy with TMZ is added to brain RT,4 as TMZ is moderately emetogenic.5,6 
Temozolomide prescribing information reports nausea and vomiting rates of 36% and 20% respectively for 
concomitant RT+TMZ and concomitant RT +TMZ with standard antiemetic treatment.7 Comparable rates of 
nausea (35%) and vomiting (26%) were reported in a recent study of Korean malignant glioma patients 
receiving such treatment.8 The National Comprehensive Cancer Network (NCCN), Multinational Association of 
Supportive Care in Cancer (MASCC), and American Society of Clinical Oncology (ASCO) publish current clinical practice guidelines addressing th e issue of RINV  
9,10,6 These guidelines recommend that patients receiving 
concomitant chemotherapy and RT treatment should be given antiemetic prophylaxis according to the emetog enicity of the chemotherapy prescribed, unless the emetic risk of the radiotherapy is higher. Given the 
moderate emetogenicity of TMZ therapy, patients with brain tumors are classified as a moderate -risk group 
for RINV.  
 
At Duke PRTBTC , we estimate the RIN V rate to be approximately 50% without the use on ondansetron . 
Despite prophylaxis against nausea and vomiting during cranial RT and concomitant temozolomide therapy, 
Stupp 
4,11 reported a  threefold  (14% - 40/287) increase in the grade 2- 4 nausea/v omiting rate compared to a 
4% (11 /286) nausea/vomiting rate with radiotherapy alone. Without prophylaxis, up to 60% of patients 
receiving cranial radiation may experience acute nausea and vomiting, which can lead to various adverse 
effects including dehydration, electrolyte imbalance, malnutrition, and aspiration pneumonia. These 
complications can further delay/decrease the therapeutic effect of temozolomide and radiation treatment, 
ultimately leading to lower response rate s and decreased health- related quality of life (HRQoL).  
 We conducted the first phase 2 single arm trial of palonosetron (PAL), a long acting 5 -hydroxytryptamine (5 -
HT
3) receptor antagonist (5HT 3-RA), for the prevention of RINV in primary MG su bjects rece iving RT (54 -60 Gy) 
and concomitant multi -dose, daily TMZ (75 mg/m2) +/- bevacizumab.  Results from this study demonstrate 
that a 5HT 3-RA, such as PAL or ondansetron, can be safe and effective, however based on the results, there is 
still room for improvem ent of anti -emetic response related to CR rates and HRQoL, which could be addressed 
by combining a 5- HT 3-RA and NK -1-RA12. PAL was safe and effective; however, there is room for improvement 
in the CR rates and HRQoL , which may be achieved with rolapitant plus ondansetron, a potentially more 
effective combination anti -emetic regimen.   Additionally, PAL is only available as an IV injection in the United 
States whereas ondansetron can be administered orally, making it a more patient- friendly drug.  The most 
studied agents in the RINV settings are the 5HT 3-RAs, with overall moderate response and low toxicity. 
However, agents such as the tachykinin NK -1 receptor antagonist may play a role in improving response rates , 
but there need s to be further studie s in randomized controlled trials.13 
7.2 Study Agent  
Rolapitant, an FDA- approved , novel , long -acting, new highly- selective neurokinin-1 (NK 1) receptor antagonist 
(RA), in combination  with a 5HT 3-RA (i.e. ondansetron , granisetron ) and dexamethasone is a well -tolerated 
antiemetic combination that has demonstrated superiority for the prevention of highly -emetic chemotherapy 
(HEC) induced nausea and vomiting (CINV)14.   
 
In a global, randomized, double -blind, active -controlled, phase 3 multi -center study, 1369 patients receiving 
moderately -emetic chemotherapy  (MEC)  or regimens containing an anthracycline and cyclophosphamide 
were randomly allocated  (after stratification by sex) to receive either one 180 mg dose of oral rolapitant or a 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 17 of 52 
CONFIDENTIAL 
 placebo (active control) 1 -2 hours  before administration of chemotherapy. All patients also -received 
granisetron (2 mg orally) and dexamethasone (20 mg orally) on day 1 and granisetron (2 mg orally) on days 2-
3.15   The median cycle duration was 21 days with the recommended minimum dosing for Rolapitant at  no less 
than 14 day intervals . The primary efficacy endpoint was complet e response (CR: no emesis, no rescue 
medication) during the delayed (>24- 120 h ours) phase.  A significantly larger proportion of patients receiving 
rolapitant had complete responses in the delayed phase than did those receiving active control (475 [71%] vs  
410 [62%]; odds ratio 1.6, 95% CI 1.2- 2.0; p=0.0002).15 Toxicities were similar in the rolapitant and control 
groups, with the most frequently reported treatment- related treatment- emergent adverse events being 
fatigue, constipation, and headache.15 No serious adverse event was treatment -related, and no treatment -
related adverse event resulted in death.15 
 
Mechanism of action:  Rola pitant is a  selec tive and comp etitive  antagonist of  hum an subst ance P/ NK 1 
receptor s. Rola pitant do es not h ave significant affini ty for the NK 2 or NK 3 receptors or f or a ba ttery of 
other receptor s, transporters, enzyme s and ion channels.   Rola pitant is a lso active in animal mod els of 
chemotherapy- induced eme sis. 
 
Pharmacodynamics:  NK 1 Receptor O ccupanc y - A Human  Positron Emiss ion Tomo graphy (P ET) study with 
rolapitant demonst rated that rola pitant crosses the blood b rain barrier a nd occupies brain NK 1 recepto rs.  A 
dose-depe ndent in crea se in m ean NK 1 rece ptor occ upancy wa s observed in the  dose  range fr om 4.5 mg  to 180 
mg of rola pitant. At the  180 mg  dose  of rola pitant, the mean NK 1 rece ptor  occupancy wa s 73% in the  striatu m 
at 120 hours after a single dose  adm inist ration in h ealthy su bjects.  The re lationship b etwee n NK 1 rece ptor 
occupancy an d the  clinical efficacy of rola pitant has not b een establish ed. 
 
Cardiac Electrophysiolo gy - In a thoroug h QT stu dy, rolapitant a t dos es up to 4 times higher tha n the  
recomme nded do se had no si gnificant effects on the QT int ervals 
 
Pharmacokinetics :  Abso rption  - Following  a single dose administ ration of  180 mg  rola pitant under fa sting 
conditions to h ealth y subj ects, rolapitant was m easu rable in pl asma betw een 30 minut es and the p eak pl asma 
concentration (Cmax) for rola pitant w as reac hed in about 4 hours, and m ean Cmax was 968n g/mL (%CV:28%).   
Following  multiple  oral dose s 9 to 45 mg  once daily of rola pitant; accumul ation of rola pitant was 
approx imately 5-f old.  The  systemic exposu res (Cmax and AU C) to rola pitant in crea sed in a dose-pr oportiona l 
manner wh en the  dose  of rola pitant in crea sed from 4.5 mg to 180 m g.  With an increa se in dose  by 4 tim es 
from the  recomm ended clinical dose  of 180 m g, the  Cmax and AUC  of rola pitant in crea sed by 3.1 fold and 3.7 
fold, resp ectively. Concomit ant a dmin istration of a hig h fat m eal did  not si gnificantly affect the 
phar macokin etics of rola pitant after a dmin istration of 180 mg rola pitant.  
 
Distribution  - Rola pitant w as highly prote in bound to  hum an plasma (99.8 %).  The a pparent volume  of 
distribution (Vd/F) wa s 460  L in healthy subjects, indicating an extens ive tissue  distribution of rola pitant.  In a 
popul ation ph armacokin etic analys is of rola pitant, the Vd/F  was 387  L in cancer patie nts. 
 
Elimin ation - F ollowing  single oral doses (4.5 to 180 m g) of rola pitant, the  mean t erminal half-life (t 1/2) of 
rolapitant ranged from 169 to 183 hours (app roximately 7 days) a nd was ind ependent of  dose. In a popul ation 
phar macokin etic analy sis, the app arent total clearance (CL/F) of rola pitant w as 0.96 L/hour  in cancer patie nts.  
 
Meta bolism - Rola pitant is m etabolized pr imarily by CYP 3A4 to  form a major active meta bolit e, M19 (C4- 
pyrrolidin e-hydroxylated rola pitant). In a mass balance study, the  meta bolite M 19 w as the  major ci rculating 
meta bolit e. The forma tion of M19 was significantly delayed with the  median Tmax of 120 hrs. (range : 24-168 
hours) a nd the  mean half- life of M19 wa s 158  hours.  The  exposu re ra tio of M19 to rola pitant w as 
approximately 50% in pl asma. 
  
Excretion - Rola pitant is el imin ated pr imar ily throug h the  hepatic /biliary route .  Following  administ ration of a 
single oral 180  mg dose of [14C]-rola pitant, on average 14.2%  (range 9% to 20 %) a nd 73% (range 52% to 89 %) 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 18 of 52 
CONFIDENTIAL 
 of the dose  was recovered in  the urine and fece s, resp ectively over ~ 6 weeks . In pool ed sa mple s collec ted ov er 
2 weeks, 8.3%  of the dose  was recovered in the  urine primar ily as metabolit es and 37.8%  of the dose  was 
recovere d in the  feces primarily a s unchange d rolapitant. Un change d rolapitant or  M19 w ere not f ound in 
poole d urine sample .  
 
Specific P opul ations - Age , Sex a nd Race/Ethni city - P opul ation ph armacokin etic analyse s indi cated that age , 
sex a nd race had no sig nificant imp act on the  pharmacokinetics of rola pitant. 
 
Pregnancy: There are no available data on rola pitant use in pregna nt wo men to in form any drug-a ssociate d 
risks.  In anima l reproduc tion studi es, th ere were no tera toge nic or e mbryo-feta l effec ts obs erved with o ral 
administra tion of rola pitant hydroc hloride in rats and rabbits du ring the period of organogene sis a t dos es up 
to 1.2 tim es and 2.9 ti mes, resp ectively, the maxi mum recomme nded hum an dose  (MR HD).  In the  U.S. 
gene ral popul ation, the  estimated bac kground r isk of  major birth defects and miscarr iage in clinically 
recognized pregnancies is 2% to 4%  and15%  to 20 %, resp ectively. 
 
Hepa tic Impairme nt- Following  administ rations of a single dose of 180 mg rolapitant to patients with mild 
hepatic impairment (Child -Pugh Class A), the pharmacokinetics of rolapitant were  comp arable with those  of 
healthy subjects. In patie nts with mod erate hepa tic impairment (Child -Pug h Class B), the  mean Cmax was 25%  
lower while  mean AUC  of rola pitant w as similar c omp ared to those  of healthy subjects.  The  median Tmax for 
M19 w as delaye d to 204 hours in patie nts with m ild or mod erate hepa tic impairment c omp ared to 168 hours 
in healthy subjects.  The phar macokin etics of rola pitant w as not s tudied in patie nts with  severe hepa tic 
impairment (Child -Pug h Class C). 
 
Renal I mpairme nt- In popul ation ph armacokinetic analyse s, crea tinine cl eara nce (CL cr) at baseline did not 
show a si gnificant effect on rolapitant phar macokin etics in ca ncer patie nts with m ild (CLcr: 60 to 90 mL/min)  or 
mod erate (CLcr : 30 to 60 mL /min)  rena l imp airment co mpared to ca ncer patie nts with no rmal kidn ey funct ion.  
Informa tion is insu fficient for the effect of sev ere renal Impairme nt. The  pharmacokin etics of rolapita nt w as 
not studi ed in patients with end-stage ren al disease  requir ing hemodi alysis. 
 
Drug    Interaction Studies-Effect of Other Drug s on Rola pitant - Rola pitant is a  subs trate for CYP 3A4.  
 
CYP3A4   indu cers - Conc omit ant a dmin istration of  a CYP 3A4 indu cer significantly decrease d the sy stemic 
exposu re to r olapitant. Whe n 600  mg rifampin (CYP3A4 inducer) was administered on ce daily for 7 days b efore 
and 7 d ays after a dminist ration of a single dose  of 180 mg  rola pitant, the  mean Cmax of rola pitant w as 
reduced by 30% a nd the  mean AUC  was reduce d by 85%  comp ared to administ ration of rola pitant a lone.  The  
mea n half- life of rola pitant decrease d from 176 hours without ri fampin  to 41 hours with concurre nt rifampin .  
Strong CyP3A4 inducers (e.g.,        rifampin ) significantly re duce d pla sma con centrations of rola pitant, which can 
decrease  the efficacy of rola pitant; avoid u se of rola pitant in patie nts who requi re chronic  administ ration of 
such drug s. 
 
CYP3A4   inhibito rs: No c linically sig nificant effec t was see n on the  pharmacokin etics of rola pitant wh en 
ketoconazole , a strong CYP 3A4 inhibitor  was administ ered with rolapitant.  Concurrent a dminist ration of 400 
mg ketoc onazole  once daily for 21 d ays following a s ingle 90 mg dose  of rola pitant, did not  significantly affect 
the C max of rolapitant while  the AUC increa sed by 21%. 
 
Effect of Rola pitant on O ther Drugs – Eff ects of rola pitant on CYP450 enzyme s and transpo rters is su mmarized 
below:  
 
CYP3A4  subst rates: Rola pitant is n either a n inhibitor  nor a n indu cer of CYP 3A4,  therefo re, no do sage 
adjustme nt for dexametha sone  (CYP3A 4 subst rate) is needed wh en co-a dminist ered with  rola pitant. 
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 19 of 52 
CONFIDENTIAL 
 Dexametha sone:  Rola pitant had no si gnificant effects on the  pharmacokin etics of d exametha sone  when oral 
dexametha sone  was administ ered day s 1-3 after a single 180 mg dose  of rola pitant w as co-a dminist ered on 
Day 1.  
 
Ondansetron: Rola pitant had no sig nificant effects on the phar macokine tics of intravenous ond ansetron 
when conc omit antly administ ered w ith a single 180 mg dose  of rola pitant on the s ame day. 
CYP2D6   inhibitor : 
Rola pitant is a  (1) moder ate inhibitor of CYP 2D6 (i.e. concomitant use  with Thio ridazine is contra indicated due 
to QT prolongation and Torsa  des de Pointes.  Avoid use of rola pitant with pimo zide,); (2) an in hibitor of B reast-
Cancer-Resistance Prote in-BCRP  (i.e. Topetecan, Methotrexate;  Use the lowest effective dose  of rosuv astatin), 
and (3) an  inhibitor of P-glycoprote in (P-gp) (incr ease d plasma concentra tions of digoxin, or  other P-g p 
subst rates, may re sult in pot entia l adverse reactions.  Monitor for in crea sed digoxin concentrations) .  Refer to 
package insert .  The Table below  is a summary of the effec ts of  the c linical dose  of rola pitant on the 
phar mac okin etics of co- a dminist ered drugs: 
 
Table 2: Effects of Rolapita nt on the Pharmacokin etics of Co-administe red Drugs*  
 
  
Enzyme/ Co-administ ered drug  
Day 1 % Change for Co-Administered  Drug 
with rolapitant Day 8 without rol  
apitant 
transporter    
  Change in 
Cmax Change in 
AUC  Change in 
Cmax Change in 
AUC  
CYP2D6 Dextromethorphan 30mg  120%  ↑ 160%  ↑ 180%  ↑ 230%  ↑ 
BCRP Sulfasalazine 500 mg  140%  ↑ 130%  ↑ 17%  ↑ 32%  ↑ 
P-gp Digoxin 0.5 mg  70%  ↑  30%  ↑ n/a  n/a 
* A single dose of 180 mg rolap itant w as adminis tered on day 1; the in teracting drug w as adminis tered on day 1 w ith rolapitant 
and alone on day 8; ↑  Denotes an average incr ease in exposure by the per centage ind icate d. n/a: Not stud ied 
 
Rationale for use in gliomas:  Th e oral combination of rolapitant plus ondansetron h as not been studied in the 
prevention of RINV using multi -dose  chemothera py in individuals with malignant glioma. Additional 
advantages to using rolapitant plus ondansetron in the setting of radiation with concurrent multi -dose oral 
chemotherapy are that it avoids side effects associated with intravenous administration (e.g. palonosetron) 
and eliminates treatment room costs. Furthermore, rolapitant, as opposed to the aprepitant or netupitant, is 
not a CYP3A4 inhibitor or inducer of for common drugs used in glioma patients (e.g. dexamethasone , enzyme -
inducing anticonvulsants , or irinotecan) thus reducing drug-induced side effects.  The NK 1 antag onist EM END ® 
(aprepitant) was a pprov ed by the US Food  and Dru g Adminis tration and by the  European  Medicines Agency  for 
the prev ention o f acu te and delayed CINV associat ed with highly emetic chemotherapy (HEC- i.e. high dose 
cisplatin) and MEC w hen used in combi nation with a 5-HT 3 anta gonist and a corticosteroi d. Dosage adj ustment 
of conco mitantly administer ed drugs is nece ssary with apr epitant, whi ch is a mix ed induce r/inhibitor of 
cytochrome P 450 (CYP) 3A4 and also affects ot her CYP en zymes. Rolapit ant has been  free of c linically relevan t 
drug interactions in studi es condu cted to date, has r apid and good brain penetration, whi ch m ay contri bute to 
its quick onset of acti on, and a long half-life that a llows for dosi ng only once  during ea ch cycl e of 
chemotherapy. PET occupancy  studi es as well as c linical efficacy da ta supp ort t he use of only a single dose  of 
rolapitant to prote ct pa tients for 5 days fro m CINV. Rolapitant has been selected as a promisi ng age nt to 
addr ess this and other shortcomings o f existing therapy. Ultimately, rolapitant plus ondansetron may 
improve overall efficacy (CR rates), cost, HRQoL and patient satisfaction . 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 20 of 52 
CONFIDENTIAL 
 7.2.1 Pre-clinical experience (as noted in the Rolapitant Investigato r’s 
brochure)  
Rolapitant has been evaluated in a series of non-clinical toxicity studies of up to 6 months du ration in 
rats and up to 9 months duration in monkeys by oral administration and up to 14 da ys duration in rats 
and up to 1 month duration in monkeys by intravenous  (IV) infusion. Developmental and  reproduc tive 
toxicity studies, genetic toxicity studies, and safety pha rmacology studies were also conduct ed. In 
addition, genetic toxicity studies and a safety pha rmacology study were conduc ted with the 
pharmacologically active metaboli te SCH720881.  Furthermore, 2-year oral carcinogenicity studies of 
rolapitant in rats/mice have been  completed. 
 
Major findings in the non-clinical toxicity studies reported to date are convulsions in rats, mice, and  
monkeys at high lethal or near lethal doses (oral administration) and in monkeys (after IV infusion) as 
well as developmental and reproduc tive findings in female rats. For convulsions,  exposu re margins have 
been  identified in the non-clinical spec ies relative to clinical e xposu re data at an oral dose  of 200 mg and 
there has been  no evidence  of treatment- related seizures in the completed clinical trials. Since the 
rolapitant clinical de velopment p rogram has not nor will include women who are pregnant or 
attempting to beco me pregnant, the findings in the developmental and reproductive studies in rats are 
not cons idered relevant for the CINV clinical trials. The mouse  carcinogenicity study  with rolapitant was 
negative; the rat car cinogenicity study showed a non-significant increase  in thyroid follicular cell tumors 
and beni gn adrenal medullary tumors. 
7.2.2 Clinical experience  (as noted in the Rolapitant Investigator’s brochure  
and the  package insert)  
The total nu mber of subjects exposed  to oral rolapitant is approximately 2,800 which include 1,567 CINV 
patients and 1,231 healthy volunteers or pa tients from se veral add itional Phase  1 and  Phase  2 studies. 
Rolapitant was well tolerated at single doses up to 800 mg or as  a once- daily dose  up to 50 mg for 10 
days. Orally administered rolapitant was completely bioavailable, rapidly abso rbed,  and slowly cleared. 
Maximum concentr ations of a 200 mg dose  were app roximately 1000 ng/mL and were achieved by 
approximately 4 hours. The half-life was app roximately 170 hours  (average), suggesting that a single 
dose  may be sufficient to prevent CINV dur ing both the acute and delayed phases  of CINV. Rolapitant is 
highly bound  to plasma proteins, with an unbou nd (free) fraction of <1%. Urinary excretion of the dose  
is minor, and  the major route of elimination is via the feces . Rolapitant is extensively metabolized by 
oxidation, p rimarily to SCH 72088 1, an equipotent h uman NK1 RA. The formation and e limination of SCH 
720881 are slow. 
 
In phase  1 drug interaction studies, administration of rolapitant d id not alter the pha rmacokinetics of 
midazolam, dexamethasone  or ondanse tron, dr ugs metabolized by cy tochrome P450 3A4. This indicates 
lack of a clinically relevant inhibition of CYP3 A4 by rolapitant. Moreover, the PK of repea ted doses of 
dexamethason e was also unaffected by a single 200 mg oral dose of rolapitant, indicating a lack of 
significant CYP3 A4 induc tion by rolapitant or its metabolite. Inhibition of CYP3 A4 by conco mitant agents 
is unlik ely to affect the PK of single doses of rolapitant, since concen trations of both rolapitant and the 
active metabolite SCH 720881  were unaffected by repeated daily oral doses (400 mg) of the potent 
CYP3 A4 inhibitor ketoconazole. 
 
Repea ted administration of daily rifampin 600 mg (as 2 x 300 mg), a strong CYP3 A4 induce r, was 
obse rved to induce  the metabolism of rolapitant (4 x 50 mg) such  that a 1.5-fold reduction in Cmax and 
a 6- to 8-fold reduc tion in AUC 0-last and AUC 0-inf were obse rved along with a reduc tion in half-life from 
176 hrs. to 41 hours. 
 Co-administration of a single 200 mg oral dose  of rolapitant with a single 0.5 mg oral dose  of digoxin led 
to increases  in C
max and AUC 0-96h values for digoxin by 71%  and 30%, respec tively. No clinically 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 21 of 52 
CONFIDENTIAL 
 meaningful effects on pharmacod ynamic responses to digoxin were obse rved; therefore, rolapitant may 
have modest effects as an inhibitor of P-glycoprotein (P-gp). 
 
In a recen tly conduc ted drug interaction study  to assess the effect of rolapitant on the pha rmacokinetics 
of specific probe substrates, p reliminary results indicate that rolapitant inhibited the metabolism  of 
dextromethorphan, a  CYP2 D6 substrate, and su lfasalazine, a BCRP substrate sugges ting that rolapitant is 
a mild to moderate inhibitor of these  enzymes. Therefore, dos age adjustments may be warranted for 
sensitive CY2D6 subs trates and/or BCRP transp orter substrates when given conco mitantly with 
rolapitant, Rolapitant did not, however, alter the pharmacokinetics of tolbutamide, omeprazole, 
efavirenz or  repaglinide, drugs metabol ized by CYP2 C9, CYP2 C19, CYP2 B6, or CYP2C8 respec tively. In a 
recen tly conduc ted PK study in subjects with impaired hepa tic function, preliminary results indicate 
comparable rolapitant PK profiles were obse rved in subjects with mild hepa tic impairment and a slight 
decrease  in exposu re with subjects with moderate hepa tic impairment when compared to healthy 
subjects. Therefore, dose adjustment for rolapitant when adm inistered to patients with mild to 
moderate hepatic impairment is not required.  Subjects with severe hepa tic impairment were not 
evaluated in this study. 
 
A hu man ECG study demonstrated no effects of rolapitant 200 mg or 800 mg (4 times the therapeutic 
dose) on the QTc interval. A clinical PET study demonstrated that single oral doses of rolapitant ranging 
from 5 to 200 mg can block the occupancy of cortical NK 1 recep tors by the se lective PET ligand11 C-
GR205171.  After a 200 mg dose, over 90% of central NK 1 recep tors remained blocked for at least  5 days. 
 
A multicenter, rando mized, doub le-blind, ac tive- and placebo -controlled Phase 2 study  was conduct ed in 
patients undergoing surgical procedures to evaluate the effect of rolapitant monotherapy at doses  of 5 
to 200 mg for the prevention of PONV post-anesthesia. Response rates for the primary endpo int (no 
emetic episodes during the first 24 hrs. post-operatively increased  with increasing rolapitant dos e, with 
maximum respon se rate of 86.5% in the rolapitant 200-mg group. Subjects administered rolapitant 
doses of 20, 7 0, or 200 mg were significantly more likely to have no emetic episodes for 0 to 24 hrs. than  
subjects given placebo, and  the level of  significance was dose  related. In this study there was no pattern 
of dose  or treatment depende ncy in the incidence  of AEs. The most com mon (≥10%  of subjects) 
treatment-emergent AEs were constipation, headache,  pruritus, pos toperative GI disorder, hypotension, 
and dizziness. A total of 90 subjects (17%) in the active treatment groups e xperienced  AEs that were 
cons idered at least possibly or probab ly related to treatment co mpared with 17 (17%) of 103 placebo  
subjects. There were no appreciable safety concerns and  no dose-related effects noted in clinical 
labor atory, vital si gn, or ECG data. 
 
In study P04351  a dose  range-finding phase  2 study was conduct ed in 454 patients receiving HEC (≥70 
mg/m2 cisplatin-based  chemotherapy). The primary objective was to demonstrate that ad ministration of 
rolapitant, at doses  between 10 and 200 mg, along with ondanse tron and de xamethasone, reduc ed the 
incidences  of both acute and delayed CINV. A dos e-response trend was generally obse rved for all 
efficacy endpo ints, including complete response  (defined as  no emetic episodes and no rescue  
medication), no emesis, no  nausea, no  significant nausea, total control, and complete protection 
(defined as no emesis, no rescue  medication, and  maximum nausea  VAS <25 mm on a 0 to 100 mm 
scale). For the  200 mg group, the o verall (0-120 hrs.) complete response  rate was 62.5% co mpared with 
46.7% for placebo  (p = 0.032).  For the acute phase, the response  rate was 87.6% vs. 66.7% (p = 0.001); 
for the de layed phase,  the response  was 63.6% vs. 48.9% (p = 0.045). At lower rolapitant dosage levels, 
complete respon se rates did not ach ieve statistical si gnificance.  The rolapitant 200  mg dose  group also 
demonstrated significantly greater rates of no emesis and no significant nausea  in the overall, acute and 
delayed phases  than the control group. Kaplan-Meier curves co mparing time to first event showed 
sepa ration from con trol starting before 6 hrs. which represents a quicker on set of action that has  been 
demonstrated with other agents in its class. 
 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 22 of 52 
CONFIDENTIAL 
 In this dose  range-finding study the incidences  of treatment-emergent ad verse events (AE) and se rious 
adverse events (SAE) were similar across all treatment groups. The most com mon (≥10% of subjects) 
treatment-emergent ad verse events in the active treatment groups were nausea,  fatigue, vomiting, 
constipation , and diarrhea. Overall, SAEs occur red in 52 (11%) of 454 randomized subjects during Cycle 
1 of chemotherapy. The most c ommon (≥1% of subjects) SAEs were febrile neutropen ia, neutropenia, 
vomiting, dehydration, nause a, pneum onia, and renal failure. All SAEs were considered unlik ely related 
to treatment except  for one  occur rence  each  of dizziness (10-mg dose group), elevated blood creatinine 
(100-mg dose group), and convulsions (100-mg dose  group) which were cons idered by the investigator 
to be at least poss ibly related to treatment. Confounde rs for dizziness and elevated creatinine were 
conco mitant chemotherapy and for con vulsion was a previous history of convulsions and hy pona tremia 
at the time of the event. The  incidence of study drug discontinuation because  of AEs was similar across 
treatment groups  and ranged from 2% to 7%. Results from clinical labor atory tests, measurements of 
vital signs, and ECGs showed no appreciable safety conce rns and no dose -related effects. 
 
The results from the dose range-finding study  showed rolapitant administered as a single dose of 200 
mg with a 5-HT3 recep tor an tagonist and dexamethasone  to be highly effective in the p revention of CINV 
following HEC, together with data from the Phase  1 PET study , led to the dose  selection and design of 
three global  multicenter, rando mized, parallel-group, doubl e-blind, ac tive-controlled phase  3 studies 
conduc ted in subjects receiving HEC (P04832  and Study P04833)  and in subjects receiving MEC (Study 
P04834 ). 
 
These  studies were designed to evaluate the efficacy  of a single dose  of rolapitant 200 mg ad ministered 
orally with granisetron and dexamethasone  compared to placebo  administered with granisetron and 
dexamethasone  for the prevention of delayed phase  CINV (>24 to 120 hrs.). The primary endpo int of all 
three studies was achieved.  Specifically, the proportion of sub jects who had no emesis and no use of 
rescue medication during the delayed phase  of CINV, following initiation of HEC or MEC, was significantly 
higher for sub jects receiving rolapitant compared with subjects receiving placebo (71.4% vs. 60.9%, 
respec tively, p < 0.001). Likewise, the proportion of subjects who had no emesis and no use of rescue  
medication was significantly higher for su bjects receiving rolapitant compared with sub jects receiving 
placebo during the acute phase (< 24  hrs.) (83.5% vs. 78.7%, respe ctively, p = 0.003) and during the 
overall phase  (0-120 hrs.) (68.7% vs. 58.1%, respec tively, p < 0.001). Multiple seconda ry and tertiary 
endpo int comparisons favored the rolapitant group in the individual s tudies and in the pool ed analyses 
and contribute additional su pport for the benefit of rolapitant during the delayed, acute and overall at 
risk period (0 to 120 hrs.) for patients receiving emetogenic chemotherapy.  In addition, rolapitant was 
safe and well tolerated. No AEs were clearly attributable to administration of rolapitant. Neurological 
and other clinical /laboratory examinations did not d etect speci fic safety signals ascribed to rolapitant. 
 
A single ascend ing dose  (SAD)  and multiple ascending dose  (MAD) asse ssment study of intravenous  
rolapitant in healthy volunteers was completed. The study’s primary objective was to asse ss the safety 
and tolerability of intravenous  (IV) rolapitant.  A total of 57 subjects with a similar mean age of 37 years 
across each  dose group were enrolled into Part 1 (SAD) and a total of 20 subjects with a similar mean 
age of 38 years across each dose  group were enrolled into Part 2 (MAD). 
 
Part 1 evaluated the safety and tolerability of intravenous  rolapitant administered as a single ascendi ng 
dose  (20, 50,  100,  150, 185 and 200 mg) over 30 or 45  minutes. Intravenous  (IV) rolapitant administered 
as a single ascendi ng dose of up to 200 mg was well tolerated. There were no TEAEs resulting in death 
or SAEs reported in this study.  All TEAEs were mild or moderate and had a single occu rrence.  The 
majority of TEAEs resolved spontaneously. No dose -dependent adv erse events were obse rved, as 
indicated by the similarity of incidences  of treatment-emergent and treatment-related emergent  AEs 
among the different dose groups.  
 
Part 2 evaluated the safety/tolerability of intravenous  rolapitant administered as a multiple ascending 
doses (20, 40, and 60 mg) over 30 minutes.  Intravenous (IV) rolapitant of 60 mg IV administered for 10 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 23 of 52 
CONFIDENTIAL 
 days was well tolerated. There were no serious TEAEs or TEAEs resulting in death and no TEAEs leading 
to discon tinuation of dos ing or discon tinuation in this study. TEAEs were primarily mild and resolved 
spon taneous ly.  Infusion-related adverse events, when they occurr ed, were generally mild, limited to 
the catheter site (mild pain or erythema), resolved and required only ice pack or removal of the IV and  
were most likely assoc iated with the placement and manipulation of catheters, and PK sampling. There 
were no clinically significant labor atories, vital signs, physical or ECG findings in any of the subjects 
overall or within each  dose group.  
 
Rolapitant Efficacy  in the CINV prevention  
The efficacy of rolapitant for the prevention of CINV was initially evaluated in a phase  2, dose range-
finding study (Study P04351 ).  In this study, a statistically significant improvement in the p rimary 
efficacy  endpo int of complete response  (CR) (defined as no vomiting and no use of rescue  medication 
during the overall 120 -hour p hase of CINV follow ing initiation of che motherapy) was observed in the 
rolapitant 2 00 mg group compared to control.  Further, a statistically significant greater proportion of 
subjects in the rolapitant 200 mg group achieved CR in the acute and delayed phases  compared with 
control.  As further suppo rt to the effectiveness of rolapitant in the treatment of CINV following HEC, a 
statistically significant difference  in the rates of emesis and no significant nausea  were observed in all 
3 phases  compared to control. The results of this study , together with data from the phase  1 PET 
study led to the dose se lection and design of three phase  3 studies, including two studies conducted in 
subjects receiving HEC (Study P04832  and Study P04833) and one conduc ted in subjects receiving MEC 
(Study  P04834) . 
 
All three phase  3 studies were designed to evaluate the efficacy  of a single dose  of rolapitant 200 mg 
administered orally with granisetron and dexamethasone  compared to placebo ad ministered with 
granisetron and dexamethaso ne for the prevention of delayed phase  CINV (>24 to 120 hrs.).  Studies 
P04832  and P04833 were conduc ted in subjects receiving HEC ( i.e., that receiving ≥60 mg/m2 and Study 
P04834  was conduct ed in subjects receiving MEC. 
 
The primary endpo int of all three phase  3 studies was achieved. Specifically, the proportion of 
subjects who did not e xperience  emesis or use rescue  medication during the delayed phase,  >24 
through 120 hrs., following initiation of HEC or MEC, was significantly higher for su bjects receiving 
rolapitant compared with subjects receiving control. Multiple seconda ry and tertiary endpo int 
comparisons favored the rolapitant group in all studies and further suppo rt the benefit of rolapitant 
during the entire at risk period (0-120 hrs.) for pa tients receiving HEC or MEC. Efficacy findings for 
rolapitant were shown to be generalizable across multiple subgroups including gende r, region, age, 
and race, and  receipt of concomitant emetogenic chemotherapy. The Kaplan-Meier curve depicting 
time to first emesis or use  of rescue  medication which sug gests that rolapitant provides a protective 
effect in the acute phas e, with sepa ration of the cu rves occu rring early after ad ministration of 
chemotherapy.  This sepa ration continues  to increase  during both the acute and delayed phases.  In 
addition, the impact of rolapitant in reduc ing the negative effects of CINV on  daily life, was clearly 
indicated by the higher proportion of subjects treated with rolapitant who reported less impact on 
daily life with respe ct to both the vomiting and nausea  domains of the FLIE. 
 
In conc lusion, rolapitant demonstrated statistically and clinically meaningful p revention of CINV 
across four global, adequate, well-controlled clinical studi es and the findings suppo rt an indication 
for rolapitant, when used  in combination with a 5-HT3-RA and de xamethasone,  for the prevention of 
nausea  and vomiting assoc iated with initial and  repea t cou rses of HEC or MEC. The studies enrolled a 
broad popu lation of sub jects based on age, gender, race and region with cons iderable comorbidities 
who were unde rgoing myelosuppr essive chemotherapy for a variety of cance rs. A summary of 
results for co mplete response  by CINV Phase are presented in Table 3. 
 
 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 24 of 52 
CONFIDENTIAL 
 Table 3: Complete Response  by CINV Phase  and Study 
 
 
 
Study Endpointa  
Rolapitant 
n / N (%)  
Control 
n / N (%) Rolapitant 200 mg vs. Cont rol 
Odds Ratio (95% CI)b P-valueb 
Complete Response – Delayed Phase 
HEC (P 04351) 56/ 88  (63.6) 44/ 90 (48.9) 1.9 (1.0, 3.4) 0.045 
HECs  Pooled 382/  535 (71.4) 322/  535 (60.2) 1.6 (1.3, 2.1) <0.001 
HEC (P 04832) 192/  264 (72.7) 153/  262 (58.4) 1.9 (1.3, 2.7) <0.001 
HEC (P 04833) 190/  271 (70.1) 169/  273 (61.9) 1.4 (1.0, 2.1) 0.043 
MEC (P 04834) 475/  666 (71.3) 410/  666 (61.6) 1.6 (1.2, 2.0) <0.001 
HECs /MEC P oole d c 857/ 1201 (71.4) 732/ 1201 (60.9) 1.6 (1.3, 1.9) <0.001 
Complete Response – Acute Phase 
HEC (P 04351) 78/ 89 (87.6) 60 /90 (66.7) 3.6 (1.7, 7.8) 0.001 
HECs  Pooled 447/  535 (83.6) 410/  535 (76.6) 1.6 (1.1, 2.1) 0.004 
HEC (P 04832) 221/  264 (83.7) 193/  262 (73.7) 1.8 (1.2, 2.8) 0.005 
HEC (P 04833) 226/  271 (83.4) 217/  273 (79.5) 1.3 (0.8, 2.0) 0.233 
MEC (P04834) 556/  666 (83.5) 535/  666 (80.3) 1.2 (0.9, 1.6) 0.143 
HECs /MEC P oole d c 1003 /1201  (83.5) 945/ 1201 (78.7) 1.4 (1.1, 1.7) 0.003 
Complete Response – Overall Phase 
HEC (P 04351) 55/ 88 (62.5) 42/ 90 (46.7) 1.9 (1.1, 3.5) 0.032 
HECs  Pooled 368/  535 (68.8) 313/  535 (58.5) 1.6 (1.2, 2.0) <0.001 
HEC (P 04832) 185/  264 (70.1) 148/  262 (56.5) 1.8 (1.3, 2.6) 0.001 
HEC (P 04833) 183/  271 (67.5) 165/  273 (60.4) 1.4 (1.0, 1.9) 0.084 
MEC (P 04834) 457/  666 (68.6) 385/  666 (57.8) 1.6 (1.3, 2.0) <0.001 
HECs /MEC Poole d c 825/ 1201 (68.7) 698/ 1201 (58.1) 1.6 (1.3, 1.9) <0.001 
    Abbreviations:  
    CI=confidence interval; CMH=Cochr an-Mantel Haenszel; HEC= highly emetogenic chemotherapy; MEC=mode rately emetogenic chemotherapy. 
a Compl ete response is defined as no emesis or use of rescue medi cation. 
b P04351 :  Odds ratio, CI and p-value are from logistic regression model with effects for treatment, concomitant eme togenic chemotherapy, and sex. P04832, 
P04833, P04834:  Odds ratio, CI and p-value are from the CMH test adjusted for study (where studies are pool ed) and gende r effect. 
     c HECs/MEC Pooled=P04832, P04833,  P04834. 
 
 
 
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 25 of 52 
CONFIDENTIAL 
 Summary of Three Robust Clinical Studies  
In two multice nter, randomized, doubl e-blind, par allel group,  controlled clinical studie s (Study 1 and Study 
2), the  rolapitant ( VARUBI) reg imen (VARUBI, g ranisetron a nd dexametha sone) wa s comp ared with c ontrol 
therapy (placebo, g ranisetron and dexametha sone) in patients receivi ng a HEC chemoth erapy reg imen that 
included cisplatin >60 m g/m2. See Table 4  for the trea tment regimens. 
 
Table 4:  Treatment Regimen s in Studies 1 and 2  
 Day 1 Day 2 to 4 
VARUBI Regimen 
Oral VARUBI† 180 mg none  
Oral Dexamethasone 20 mg‡ 8 mg  twice daily 
Intravenous Granisetron 10 mcg/kg § none  
Control Regimen* 
Oral Dexamethasone 20 mg‡ 8 mg twice daily 
Intravenous Granisetron 10 mcg/kg § none  
* VARUBI p lacebo was used to maintain blindi ng 
† VARUBI was administer ed 1 to 2 hrs. prior to chemotherapy treatment on Day 1 
‡ Dexamethasone w as adminis tered 30 minutes prior to chemotherapy on Day 1. There is n o drug 
interaction between VARUBI and dexam ethason e, so no dosage adj ustment for dexam ethasone r equir ed  
§ The dose of graniset ron was adminis tered 30 minu tes prior to chemotherapy on Day  1. 
  
Study  1 
A tota l o f  532 p atients wer e randomi zed to either the rolapitant ( VARUBI) reg imen (N = 266) or 
contr ol th erapy (N = 266). A tot al of 526 pa tients were included in the  evaluation of efficacy.  Of 
thos e randomi zed 42%  were wom en, 58 %  men, 67%  White, 23%  Asian, 1%  Black, and 9%  multi - 
racial/oth er/unknown. The  propor tion of patient s from No rth Am erica was 16%. Patie nts in th is 
clinical stu dy range d from 20 to 90  years of age, with a  mean age of 57 ye ars. In Study 1, 26% of 
patie nts wer e 65 years or older, with 3%  of patie nts b eing 75 ye ars or old er.  The mean cisplatin 
dose  was 77 mg /m2. During this stu dy, 82% of the patie nts receiv ed a conc omit ant 
chemothe rapeutic agent in a ddition to p rotocol-mandate d cisplatin. The  most common 
conc omit ant chemoth erapeutic agents administ er ed dur ing Cycle 1 were: gemc itabine  (17%) , 
paclitaxel (12%), fluorouracil (11%) , etoposide ( 10%), vino relbine  (9%), docetaxel (9 %), 
pemetrexe d (7%), doxorubic in (6%) and cyclophospha mide  (5%).  
 
S
tudy  2 
A tota l o f  555 p atients wer e randomi zed to either the rolapitant ( VARUBI) reg imen (N = 278) or 
contr ol th erapy (N = 277). A tot al of 544 pa tients were included in the  evaluation of efficacy. Of 
thos e randomi zed 32%  were wom en, 68 %  men, 81%  White, 14%  Asian , 1%  Black, and 5%  multi - 
racial/oth er/unknown. The  propor tion of patient s from No rth Am erica was 7% . Patie nts in th is 
clinical stu dy range d from 18 to 83  years of age, with a  mean age of 58 ye ars. In this stu dy, 27% 
of patie nts were 65 years or older, wit h 3%  of patie nts b eing 75 years or old er. The  mean 
cisplatin dose wa s 76 m g/m2. During this stu dy, 85% of the patie nts receiv ed a conc omit ant 
chemothe rapeutic agent in a ddition to p rotocol-mandate d cisplatin. The  most common 
conc omit ant chemoth erap y agents administ ered dur i ng  Cycle 1 were : vin rorel bine  (16%) , 
gemc itabine  (15%), fluorouracil (12%) , etoposide  (11%), pemetrexe d (9%), docetaxel (7 %), 
paclitaxel (7%), epirubicin (5%) a nd capecitabine  (4%). 
 
Th
e primary e ndpoint in both studi es was compl ete response  (defined as no eme tic episod es 
and no rescue medication) in the  delaye d phase ( 25 to  120 hrs.) of CINV . 
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 26 of 52 
CONFIDENTIAL 
 Study  3 
In Study 3, a multi center, randomi zed, doubl e-blin d, parall el gr oup,  controlled clinical stu dy in 
mod erately emetoge nic chemoth erapy (MEC) , the rolapitant ( VARUBI) reg imen (VARUBI, 
granisetron a nd d exametha sone) was c omp ared with control th erapy (placebo, g ranisetron a nd 
dexametha sone) in patie nts rece iving a mod erately emetoge nic chemoth erapy reg imen that 
included at least 50% of patie nts rece iving  a co mbin ation of  anth racycli ne and 
cyclophosp hamide. The  perce ntage of patie nts who receiv ed carbopl atin in Cycle 1 was 30% . 
Treatment regimens for the VARUBI a nd control arms are summar ized in Table 5 . 
 
Table 5: T reatment Regimen s in Study 3 
 Day 1 Day 2 to 4 
VARUBI Regimen 
Oral VARUBI† 180 mg none  
Oral Dexamethasone 20 mg‡           none  
Oral  Granisetron 2 mg §               2 mg once daily 
Control Regimen* 
Oral Dexamethasone 20 mg‡            none  
Oral  Granisetron 2 mg §              2 mg once daily  
* VARUBI p lacebo was used to maintain blindi ng 
† VARUBI was administer ed 1 to 2 hrs. prior to chemotherapy treatment on Day 1 
‡ Dexamethasone w as adminis tered 30 minutes prior to chemotherapy on Day 1.  
§ The dose of granis etron was adminis tered 30 minu tes prior to chemotherapy on Day 1.  
A tota l o f  1369 p atients w ere randomi zed to either the rolapitant ( VARUBI) reg imen (N = 684) or 
contr ol th erapy (N = 685) . A tot al of 1332 p atients wer e included in the  evaluat ion of efficacy. Of 
those randomi zed 80%  were wom en, 20%  men, 77%  White, 13%  Asian, 4%  Blac k, and 6%  multi - 
racial/oth er/unknown. The  propor tion of patient s from No rth Am erica was 33%. Patie nts in th is 
clinical stu dy ranged fro m 22 to 88  years of age, with a  mean age of 57 ye ars. In this stu dy, 28% of  
patie nts were 65 years or older, with 7%  of patie nts b eing 75 years or old er. The primary e ndpoint 
was complete response  (define d as no eme tic episod es and no rescu e medication) in the  delaye d 
phase (25 to 120 hrs. ) of chemotherapy- indu ced nausea and vomitin g. A summ ary of the study 
results from HEC S tudies 1  & 2, and for the MEC  Study 3 is shown in  Table 6. 
 
T
able 6:   Perce nt of Patients Receivin g Emetogenic C hemoth erapy Respo nding by Treatment Group f or the HE C 
Studies 1 and 2 and f or the ME C Stud y 3 
 
Endpoint  
HEC Stud y 1  
HEC Stud y  
MEC Study 3 
  
 
VARUBI † 
(N=264) 
Rate (%)   
 
Control † 
(N=262) 
Rate (%)   
P-Value 
Treatment 
Difference 
(95% C .I.) VAR 
UBI† 
(N=27 
1) 
Rate 
(%)  
Control  
† 
(N=273 
) Rate 
(%)  
P-Value 
Treatment 
Difference 
(95% C .I.)  
VARUB 
I† 
(N=666) 
Rate 
(%)  
 
Control † 
(N=666) 
Rate (%)   
P-Value 
Treatment 
Difference 
(95% C .I.) 
 
Primary  
Endpoi nt 
: Comple te 
Response 
in the 
Delay ed 
Phase  
 
 
 
72.7  
 
 
 
58.4  
 
 
<0.001* 
 
14.3 
(6.3,22.4)  
 
 
 
70. 
1  
 
 
 
61.9  
 
 
0.043* 
8.2 (0.3, 
16.1)  
 
 
 
71.3  
 
 
 
61.6  
 
 
<0.001* 
9.8 (4.7, 
14.8) 
 
† Granis etron and dexamethasone were used as concom itant drugs. 
* Results were obtained bas ed on the Coch ran-Mantel-Haens zel test stratified by gender. 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 27 of 52 
CONFIDENTIAL 
 
Multiple -Cycle Extension:  In Studies 1, 2, and 3, patients h ad the  option of continuing into a multipl e-
cycle extension  for up to 5 a ddition al cycles of chemoth erapy receiving  the same t reatment as 
assigned in c ycle 1.  At da y 6 to 8 following  initia tion of chemotherapy, patients were asked to reca ll 
whether they had any episode of vomiting  or retching  or nausea that interfered with no rmal daily life. 
The results are summ arized by study and treatm ent group in the f igure below.  
 
 
 
Study 1 Study 2 
 
 
  
 
  
 
  
 
 
 
 
  
 
  
 
  
 
Study 3 
 
 
Figure 1: No Emesis a nd No Na usea Interfering with Daily Life over Cycles 2-6  

Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 28 of 52 
CONFIDENTIAL 
 7.3 Study Purpose/Rationale 
The purpose of this randomized study is t o primarily assess efficacy, in addition to patient preference , patient   
satisfaction and patient compliance of rolapitant plus ondansetron  vs. ondansetron  monotherapy for the 
prevention of chemo -radiation -induced nausea and vomiting (chemo -RINV) in malig nant glioma patients 
receiving standard RT and concomitant TMZ (Stupp regimen).   
 
We conducted the first phase 2 single arm trial of palonosetron (PAL), a long acting 5 -hydroxytryptamine (5 -
HT 3) receptor antagonist (5HT 3-RA), for the prevention of RINV in  primary MG su bjects receiving RT (54- 60 Gy) 
and concomitant multi -dose, daily TMZ (75 mg/m2) +/- bevacizumab.  Results from this study demonstrate 
that a 5HT 3-RA, such as PAL or ondansetron, can be safe and effective, however based on the results, there i s 
still room for improvement of anti -emetic response related to CR rates and HRQoL, which could be addressed 
by combining a 5- HT 3-RA and NK 1-RA12. PAL was safe and effective; however, there is room for improvement 
in the CR rates and HRQoL , which may be achieved with rolapitant plus ondansetron, a potentially more 
effective combination anti -emetic regimen.  Additionally, PAL is only available as an IV injection in the United 
States whereas ondansetron can be administ ered orally, making it a more patient- friendly drug.  The most 
studied agents in the RINV settings are the 5HT 3-RAs, with overall moderate response and low toxicity. 
However, agents such as the tachykinin NK -1 receptor antagonist may play a role in improvi ng response rates , 
but there need s to be further studie s in randomized controlled trials.13 
 
The oral combination of rolapitant plus ondansetron has not been studied in the preve ntion of RINV using 
multi- dose  chemotherapy especially in individuals with malignant glioma. Additional advantages to using 
rolapitant plus ondansetron in the setting of radiation with concurrent multi -dose oral chemotherapy are that 
it avoids side effects associated with intravenous adm inistration (e.g. palonosetron) and eliminates treatment 
room costs. Furthermore, rolapitant, as opposed to the aprepitant or netupitant, is not a CYP3A4 inhibitor or inducer of for common drugs used in glioma patients (e.g. dexamethasone , enzyme -inducing anticonvulsants , 
or irinotecan) thus reducing drug- induced side effects.  The NK
1 antagonist EMEND ® (aprepitant) was approved 
by the US Food and Drug Administration a nd by the European  Medicines Agency for the prevention of acu te 
and delayed CINV assoc iated with highly emetic chemotherapy (HEC - i.e. high dose cisplatin) and  MEC when 
used  in combination with a 5-HT3 antagonist and a corticosteroid. Dosage adjustment of conco mitantly 
administered drugs is nece ssary with aprepitant, which is a mixed induce r/inhibitor of cytochrome P450 (CYP)  
3A4 and also affects other CYP en zymes. Rolapitant has been  free of clinically relevant drug interactions in 
studies conduc ted to date, has rapid and good brain penetration which may contribute to its quick onset of 
action, and a long half-life that allows for dosing only once  during each cycle of chemotherapy. Rolapitant has 
been selected as a promising agent to address this and other shortcomings of existing therapy. As described 
above , PET occupancy  studies as well as clinical efficacy da ta supp ort the use of only a single dose  of rolapitant 
to protect pa tients from CINV. Efficacy or complete response be assessed during weeks 1 -2. Complete 
response (CR) is defined as the proportion of patients without an emetic episode or u se of rescue medication 
while receiving radiation  and concomitant temozolomide).  
 
Patient -centered care as it relates to patient preference and satisfaction has become one of the major goals in 
healthcare reform and transformation. Patient centeredness is a dimension of health care quality because of 
its connection with desired aims, like safety and effectiveness. Patient centeredness and satisfaction shifts the 
control from the hands of those who give care into the hands of those who receive it. Patient satisfaction with healthcare medications has been shown to affect treatment- related behaviors such has their likelihood of 
complying and continuing to use their medication correctly.
16Thus, patient satisfaction translates into 
improved patient -centered outcomes and quality of care.  The basis for this assessment will be overall patient 
medication satisfaction/preference at the end of week 3 and 6.  More descriptive data (effectiveness, 
convenience and global satisfaction) relating to a patient’s choice will be measured as a secondary outcome by 
the reliable and validated TSQM -9 tool.   
 
Standard practice within the PRTBTC for prophylactically preventing nausea and vomiting associated with 
chemo radiation  is the administration of ondansetron.  With the administration of ondansetron orall y 1 - 3 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 29 of 52 
CONFIDENTIAL 
 times a day for multiple days, compliance is a problem within this patient population. Newer approaches to 
treatment such as  a single dose rolapitant should have fewer or minimal compliance problems.  Hence, there 
is interest in understanding patie nt efficacy and preference relative to ondansetron . Compliance of 
ondansetron vs. rolapitant and ondansetron  is also of interest.  
 
Evidenced -based guidelines and clinical research recommend that future studies should consider the use of 
5HT 3-RAs and NK1=RA  with current therapies and in other clinical settings, such as radiation therapy. Studies 
at the PRTBTC at Duke have evaluated intravenous palonosetron in RINV. However, rolapitant has not been 
studied in the prevention of RINV in malignant glioma. Rolapi tant plus ondansetron in the setting of radiation 
with concurrent oral chemotherapy (e.g. temozolomide) is advantageous in avoiding intravenous 
administration side effects and treatment room costs. Furthermore, rolapitant and ondansetron as opposed to 
onda nsetron monotherapy (up to three times a day for seven day/week ) may ultimately increase compliance 
and decrease costs. The single dose rolapitant in combination with ondansetron may be beneficial to the brain 
tumor patient population for three specific re asons: (1) rolapitant  may increase antiemetic efficacy and (2) 
compliance in patients with gliomas who often  “forge t” to take multiple oral dosed medications due to 
memory impairment ( 3) and may prevent toxicity (e.g. interaction with enzyme inducing anticonvulsants) that 
is associated with administration of other longer acting antiemetics (e.g. aprepitant). Ultimately, rolapitant 
plus ondansetron may improve overall efficacy (CR rates), cost, HRQoL and patient satisfaction . 
  
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 30 of 52 
CONFIDENTIAL 
 8 OBJECTIVES AND ENDPOINTS  
 
 Objective  Endpoint  Analysis  
Primary  Compare the efficacy of 
rolapitant plus ondansetron vs. 
ondansetron monotherapy in the 
prevention of nausea and 
vomiting, as measured by the 
overall complete response (CR) 
rate, among malignan t glioma 
patients during RT and 
concomitant TMZ  Complete response (CR) rate associated 
with rolapitant plus ondansetron and ondansetron alone during the first two 
weeks of RT and concomitant TMZ.  The CR 
rate is defined as the proportion of patients with no  emetic episode or use of rescue 
medication while receiving radiation and concomitant TMZ.  The CR rate will be 
assessed via the modified MASCC Antiemesis Tool (MAT)  within daily diary .
17 
18 See section 15.4  
  
KEY  
Secondary Assess whether malignant glioma 
patients receiving RT and concomitant T MZ are more 
satisfied with rolapitant plus ondansetron vs. ondansetron 
monotherapy for the prevention 
of RINV  The percentage of patients who prefer 
rolapitant plus ondansetron over 
ondansetron alone , as determined by 
response to the question with “Which nausea medication regimen was I most 
satisfied with?”  See section 15.5.1  
Secondary  Describe   the rationale behind a 
patient’s satisfaction with 
antiemetic preference b ased 
upon effectiveness, convenience & global satisfaction  Mean patient satisfaction scores during 
weeks 3 and 6 for effectiveness, 
convenience, and global satisfaction  for 
ondansetron pill and rolapitant plus ondansetron using the 9- item TSQM -9 
patient sa tisfaction survey .
16 Three subscales 
are computed: effectiveness (3 items), 
convenience (3 items), and global 
satisfaction (3 items).   See section 15.5.2  
Secondary  Compare the efficacy of 
rolapitant plus ondansetron vs. ondansetron monotherapy in the 
prevention of nausea and vomiting  separately , as 
measured by the resp ective CIN, 
CIV - CR rates , among malignant 
glioma patients during RT and 
concomitant TMZ  The CR outcome s for nausea will be defined 
in comparable terms (no use of rescue medication for nausea) . The CR outcome for 
vomiting will be defined in comparable term s (no use of rescue medication for 
vomiting ).
  The CIN, CIV CR rate will be 
assessed via the modified MASCC Antiemesis 
Tool (MAT)  within daily diary.  See section 15.5 .2 
Secondary  Evaluate patient compliance with 
rolapitant plus ondansetron and 
ondansetron monotherapy  The compliance rate defined as the 
percentage of days that rolapitant plus ondansetron or ondansetron alone were 
used during the six weeks See section 15.5.2  
Secondary  Assess the safety of rolapitant 
plus ondansetron in the prevention of   RINV in primary 
glioma patients receiving RT and concomitant TMZ The perce ntage of patients experiencing a 
grade ≥3 treatment -related toxicity. 
Toxicity (adverse events) will be assessed throughout the 6- week treatment period. 
This data will be collected via NCI Common 
Toxicity Criteria (CTC) (vs 4)  See section 15.5.2  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 31 of 52 
CONFIDENTIAL 
 9 INVESTIGATIONAL PLAN  
9.1 Study D esign  
This proposed single center study is a  randomized  phase II trial of rolapitant plus ondansetron vs. ondansetron 
mon otherapy  for the prevent ion of RINV in primary malignant glioma subjects receiving radiation therapy (RT) 
and concomitant multi -dose temozolomide (TMZ) . All eligible subjects should receive a planned total dose of 
54-60 Gy of radiation and 75 mg/m2 of temozolomide daily for a total of six weeks. Glioma patients will be 
randomized  in an unblinded fashion to receive one of two treatment sequences of antiemetic therapy for the 
prevention of nausea and vomiting associat ed with RT and concomitant TMZ.  
 
Sequence A involves administratio n of ondansetron alone  for 3 weeks followed by the use of rolapitant X 1 
dose plus daily ondansetron for 3 weeks; whereas , sequence B involves the use of rolapitant X 1 dose plus 
daily ondansetron for 3 weeks followed by 3 weeks of daily ondansetron alone.   For the rolapitant plus 
ondansetron weeks (1 or 4), patients will self -administer the oral rolapitant pills (180 mg dose ) X 1 dose,  1-2 
hours before the plan ned week of radiation fraction (see schema). Subjects will be given a prescription for 
ondansetro n 8 mg pills to be taken 30 minutes before their TMZ dose.  After the start of radiation therapy,  the 
type of additional rescue antiemetic medication , if needed  will be left up to the investigator’s discretion, with 
what is in the best interest of the subj ect.  Subjects will be educated that they are allowed to take rescue 
antiemetic medication in either arm.  If the subject experiences nausea and vomiting and does take a rescue 
antiemetic, the subject will be asked to record the use of additional antiemeti c in a medication log provided to 
them . Subjects will complete weekly medica tion log s and surveys (see appendices ) to capture study outcomes. 
Subjects will be told that the study is voluntary and that they may exit at any time if they wish.  
 
Approximately  170 patients will provide informed consent in order that 160 patients be randomized to either 
treatment sequence A or B. The 170 estimate is to al low for screen failures and dropout rates. All subjects 
must give written informed consent to participate in the study. Patients will be screened -28 - 0 days prior to 
the start of the study. During this time period the following information will be recorded: physical 
examination; vital signs and weight; laboratory studies (complete blood count with differential,  blood 
chemistries, liver function tests and urinalysis): medical history; concomitant medications (steroids and anticonvulsants) and predictors of RINV (irradiation site, planned dose treatment field, alcohol intake, gender, 
age etc.).  Laboratory evaluati ons, performance status, concomitant medications, and adverse events for final 
eligibility should be confirmed within 2 weeks of initiating radiation with concomitant TMZ  . Patients will 
obtain stand ard of care blood work (per local oncologist ) (complete b lood count with differential, blood 
chemistries, liver function tests).   Toxicity will be assessed based on the Common Toxicity Criterion (CTC 
version 4). The patient will be asked to complete the MASCC Antiemesis Tool (MAT-  see appendices) nausea 
and vomi ting questionnaire on day 0 (baseline) and days 1, 2, 4, and 7 of each week of radiation therapy. In 
addition, they will be asked to record their use of any antiemetic rescue medication .   
 At the end of weeks 3 & 6, the subject will be asked to fill out a  Treatment Satisfaction Questionnaire for 
Medication (TSQM -9- see appendices ) and will be asked at the end of week 6 to choose which antiemetic they 
prefer. 
9.2 Standard of Care Chemotherapy Treatment Plan  
Temozolomide is an oral alkylating agent which has dem onstrated anti -tumor activity as a single agent in the 
treatment of recurrent glioma. As stated previously, Stupp et al (2005) have demonstrated an increase in 
efficacy of temozolomide in combination with radiation therapy in the adjuvant treatment of prim ary 
malignant gliomas. In addition, the regimen was considered safe. Non -hematological grade 2 toxicities 
included: Fatigue (26%), other constitutional symptoms (7%), rash and dermatologic side effects (9%), 
infection (1%), vision (14%), and nausea and vom iting (13%). Grade 3 / 4 non- hematological toxicities occurred 
<10%: Fatigue (7%), other constitutional symptoms (2%), rash and dermatologic side effects (1%), infection (3%), vision (1%), and nausea and vomiting with a 5HT
3-RA (<1%).  Thus, this safe and s tandard regimen will be 
utilized in this protocol. Daily temozolomide therapy will be calculated at a dose of 75 mg per square meter of 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 32 of 52 
CONFIDENTIAL 
 body surface area per day and be administered 7 days a week from the first until the last day of radiation 
therapy or a total of 42 days.   Additional clinical and laboratory assessments will be at the discretion of the 
radiation therapist  and oncologist. 
9.3 Standard of Care R adiation Treatment Plan  
As dictated by the Stupp (2005) regimen, radiation therapy will be administere d as fractionated focal 
irradiation in daily fractions of 1.8 -2 Gy given 5 days a week for ~ 6 weeks for a total of 54-60 Gy. Patients will 
be followed closely by a local radiation therapist throughout treatment. The radiation therapist and oncologist 
will conduct the standard physical exams and obtain the lab work necessary for the eligibility. Additional 
clinical and laboratory assessments will be at the discretion of the radiation therapist and oncologist.  
9.3.1 Dose Definition and Schedule  
The external beam r adiation therapy (XRT) plan will be determined at the discretion of the local 
radiation therapist dependent on tumor size and location.  It should begin 2 -6 weeks after surgery.  One 
treatment of 1.8 -2.0 Gy will be given daily, 5 days per week, (30 -33 frac tions over less than seven 
weeks) for a total of 54-60 Gy. All portals shall be treated during each treatment session. Doses are 
prescribed at the maximum dose line encompassing > 95% of the target volume.  
9.3.2 Physical Factors 
Treatment shall be delivered on megavoltage machines of energy ranging from 4 to 18 MV photons. 
Selection of the appropriate photon energy  should be based o n optimizing the RT dose distrib ution 
within the target volume and minimizing dose to non -target normal tissue. Photon energies > 10  MV 
should be utilized only in dual energy beam arrangements using at least one beam with energy < 10 
MV. Source skin distance for SSD techniques or source axis distance for SAD techniques must be at least 
80 cm.  
9.3.3 Localization, Simulation, and Immobilizati on 
The patient shall be treated in the supine or another appropriate position for the location of the lesion. A head- holding device that is transparent to x -rays and provides adequate immobilization must be 
utilized at all times during planning and therapy to ensure reproducibility.  
 The initial target volume shall include the contrast -enhancing lesion and surrounding edema (if it exists) 
demonstrated on the pre- operative MRI plus a 2.0- cm margin. If no surrounding edema is present, the 
initial target volum e should include the contrast -enhancing lesion plus a 2.5-cm margin.  This primary 
target volume will be treated to 45 -46 Gy in 23- 25 daily fractions, at 1.8- 2.0 Gy per fraction.    
 
The boost volume will be based on the post -operative MRI performed during  treatment planning.  After 
45-46 Gy, the boost volume will include the contrast -enhancing lesion plus a 1.5 -cm margin or, if 
minimal contrast -enhancing lesion is present at a portion of the resection cavity on MRI, the surgical 
defect plus a 2.0- cm margin , whichever is greater at that segment of the MRI image.  The boost volume 
will be treated to an additional 14 -14.4 Gy in 7- 8 daily fractions, 1.8- 2.0 Gy per fraction. This will bring 
the total target dose to 54 -60 Gy in 30- 33 fractions. All parts of the target volumes are to receive at 
least 100% but no more than 110% of the dose at the prescription isodose line.  
9.3.4 
Treatment Planning and Safety  
Treatment plans may include opposed lateral fields, a wedge pair of fields, rotation, or multiple -field 
techniques, including intensity -modulated radiotherapy (IMRT) and volumetric- modulated arc therapy 
(VMAT). MRI -guided 3D treatment planning is necessary to assure accuracy in the selection of field 
arrangements. Isodose distributions for the primary and boost target volume are required on all patients, including those treated with parallel- opposed fields. A composite plan is required showing the 
respective target volumes. The inhomogeneity across the target volume shall be kept to a minimum. 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 33 of 52 
CONFIDENTIAL 
 The maximum dose should be  no higher than 112% of the prescription. Possible side effects include 
swelling of the brain, hair loss, localized skin irritation, low blood counts, fatigue, memory loss, hearing 
loss, nausea and/or vomiting, loss of appetite, headaches, radiation necros is (death of tissue or skin), 
and secondary cancer.   
9.3.5 Dose Limitations to Critical Structures  
The lens and cervical spine must be shielded from the direct beam at all times. The maximum dose to 
the optic apparatus (optic chiasm, optic nerves, and eyes) mus t be limited to 54 Gy, and the brain stem 
limited to 60 Gy . 
9.3.6 Safety Considerations  
Safety will be assessed throughout the six weeks of radiation and 2 weeks post radiation using adverse 
event reporting by the clinical research nurse (CRN) using the Common Toxicity Criterion (CTC versio n 
4.0). Monthly meetings conducted t o review all adverse event s and safety events with the PI, CRN, and 
CRC is standard  of practice within the PRTBTC.  
9.4 Anti- emetic Treatment 
9.4.1 Antiemetic Treatment Plan  
           Sequence A involv es administration of ondansetron alone  for 3 weeks followed by the use of 1 dose of 
rolapitant plus  daily doses of  ondansetron for 3 weeks .  Sequence B involves the use of 1 dose of 
rolapitant plus  daily doses of  ondansetron for 3 weeks followed by 3 weeks  of ondansetron alone.   For 
the rolapitant plus ondansetron weeks (1 or 4), patients will self -administer the single oral dose of  
rolapitant 1-2 hours before the first fraction of radiation  on the planned week . Subjects will be given a 
prescription for ond ansetron 8  mg pills to be taken 30 minutes before their daily TMZ dose.  After the 
start of radiation therapy , the type of additional rescue antiemetic medication , if needed  will be left up 
to the investigator’s discretion.  Subjects will be informed  that they are allowed to take rescue 
antiemetic medication in either arm  of the study .  If the subject experiences nausea and vomiting and 
does take a rescue antiemetic, the subject will be asked to record the use of an a dditional antiemetic  in 
the medication l og provided to them . Subjects will complete weekly med ication logs and surveys ( see 
appendices ) to capture study outcomes. Subjects will be told that the study is voluntary and that they 
may exit at any time if they wish.  
 
9.4.2 Missed Doses  
Patients will be reminded by the study team via a weekly phone call to take daily ondansetron and the rolapitant prior to weeks 1 or 4 of radiation depending on the assigned sequence (A vs. B).  The time 
and date of ondansetron and rolapitant administration will be recorded in the patient medication log 
(see appendices ). Subjects will be required to contact their treating physician for instructions if they 
forget to take rolapitant before the scheduled week of radi ation or ondansetron before their daily 
chemotherapy . Rescue medication (e.g. ondansetron 8 mg p.o.) will be used to make up a missed dose.  
9.4.3 
Concomitant Medications  
Prophylactic medication for the prevention of nausea and vomiting 24 hours prior to the star t of 
radiation therapy through the full course of radiation therapy is prohibited, with the exception of the 
study drugs. Corticosteroids will be allowed for treatment of cerebral swelling. Rescue medication for 
treatment of nausea and vomiting is permitte d while receiving radiation therapy at the discretion of the 
investigator. The date(s) of the rescue medication administration will be recorded in the patient medication log (see appendices ). 
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 34 of 52 
CONFIDENTIAL 
 9.5 Study Drug Blinding  
Not applicable  
9.6 Randomization  
A permuted block randomization will be used to assign patients , in an unblinded fashion, to one of two 
treatment sequences as described in Section 9.1.  A 1:1 al location ratio will be used.  
9.7 Rationale for Selection of Dose, Regimen, and Treatment Duration  
Rolapitant is a n FDA- approved,  novel long -acting new highly selective NK 1 receptor antagonist (RA ) that 
is designed to be given in combination with a 5HT 3-RA (i.e. ondansetron) to prevent CINV. Based on 
preclinical data and the half- life (170 hrs.) described previously and below, one oral rolapitant dose of 
180 mg will be administered in combination with oral daily ondansetron at 8 mg/day  to provided 
antiemetic co verage for 3 weeks of radiation  (3-half-lives for rolapitant). Sequence A involves 
administration of ondansetron alone for 3 weeks followed by the use of rolapitant X 1 dose plus 
ondansetron for 3 weeks; whereas sequence B involves the use of rolapitant X 1 dose plus ondansetron 
for 3 weeks followed by 3 weeks of ondansetron alone.   For the rolapitant plus ondansetron weeks (1 or 
4), patients will self -administer the oral rolapitant pill 1-2 hours before the first fraction of radiation on 
the planned  week ( see schema).  The rolapitant doses will be supplied by TerSera . 
9.8 Definition of Evaluable Subjects , On Study,  and End of Study 
An evaluable subject is defined as a patient who meets eligibility criteria and completes at least two 
week s of radiation for first CR and ~ 6 weeks  of radiation for additional secondary outcomes.  
9.9 Early Study Termination  
This study can be terminated at any time for any reason by the PI- sponsor.  If this occurs, all subjects on 
study should be notified as soon as possible.  Additional p rocedures and/or follow up should occur in 
accordance with Section 12.6, which describes procedures and process for prematurely withdrawn 
patients.  
10 STUDY DRUG 
10.1 Names, Classification, and Mechanism of Action  
Rolapit ant or Varubi ® (fo rmerly referred to as SCH 61 9734) is an FDA- approved potent, selectiv e, competitive 
neurokinin-1 (NK1) rec eptor antagoni st with no known activity at other pharm acologic targets .  It bind s with 
high affinity to t he hum an NK 1 receptor (K i = 0.66 nM) and competiti vely antagoniz es function al effects 
mediated by activation of the  NK 1 receptor in cultur ed cells (Kb = 0. 45 nM). The endogenous activator of 
NK 1 recep tors is t he neuropepti de Substance  P. Rolapitant does not h a ve  signific ant affinity for NK 2 or 
NK 3 rec eptors or for a battery o f other receptors, tran sporters, enzymes, and ion channels. The com pound 
is active in animal models of chemotherapy-i nduced nausea  and vomiting (C INV) and has demons trated 
efficacy in phase 2 studi es in patients re ceiving hi ghly emetog enic chemotherapy ( HEC). Becau se NK 1 RA is 
known to be effec tive in C INV have also been shown to be e ffective in postopera tive n ausea  and vomiting 
(PONV), rolapitant has also been  investigate d  and  shown to be effective in a p hase 2 st udy in the  prevention 
of PON V. 
 
The first i ndication for whi ch rolapitant is being devel oped  is the prev ention of CINV . CINV has bo th an acute 
(0 to 24 hrs.) and delayed (>24 to 120 hrs.) phase  and it was ex pected that rolapit ant will be  very eff ective in 
prev enting CINV bo th phases  in patients receiving eit her HEC or MEC agents . Cisplatin doses  >60 mg/m2 
repr esent the standa rd chemotherapy agent u sed in many clinical trials to determi ne effectiv eness  of anti-
CINV the rapies against a HEC regim en. MEC i ncludes che mother apy agents that are categoriz ed as Hesketh 3 
or 4 and include carboplatin, cisplatin (<50 mg/m2) and cycl ophospha mide regim ens such as 
cyclophospha mide 750 – 1500 mg/m2 IV alone or combi ned with other chemot herapy agents and 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 35 of 52 
CONFIDENTIAL 
 cyclophospha mide 500 – 750mg/m2 administered with other emetogenic chemotherapy (Hesketh level 3,  
other than c yclophospha mide). MEC clinical trials often include breast cancer pa tients receiving a com bination 
of intravenous  cyclopho spha mide plus an anthracycline drug such as doxorubicin or epirubicin. There are both 
acute (0 to 24 hrs.) and delayed (>24 to 120 hrs.) pha ses of CINV which are distinct after HEC but less 
differentiated after MEC. 
10.2 Packaging and Labeling  
The drug product will be supplied in blister packs containing two (2) 90 mg tablets provided by T erSera .   
10.3 Supply, Receipt, and Storage  
Study drug supplies must be stored in a secure, limited -access location under the storage conditions specified 
on the drug supply label.  Rolapitant tablets are stored at controlled Room temperature, 20 -25°C (68 -77°F); 
excursions permitted to 15 -30°C (59 -86°F).   
10.4 Dispensing and Preparation  
There is no preparation as each 90 mg pill is packaged in a separate sealed blister pack.  The study p harmacist 
will dispense 2-90 mg pills (for a total dose of 180mg) to the patients to be administered either on week 1 or 4 
depending on assigned sequence as directed by the study team.   
10.5 Compliance and Accountability  
Patients will be reminded by the study t eam to begin rolapitant during week 1 or 4 of radiation depending on 
assigned sequence.  Patients will also be reminded to take daily ondansetron. Compliance will be recorded by 
study coordinator through weekly patient questioning and patient recording in medication  log (see 
appendices).  Of note compliance is a secondary objective (see Section 15.5 ). 
10.6 Disposal and Destruction  
The ICS will either destroy or return the unused study drug at the discretion of TerSera . The investigational 
pharmacist will be responsible for performing and documenting such activities .  
10.7 Other Study Drugs (Ondansetron)  
10.7.1  Description  
Ondansetron is a  first generation 5 -HT 3-RA (serotonin -3). 
10.7.2  Source  
Onda nsetron (Zofran) is commercially available and will not be provided in this study.  
10.7.3  Dosage and Administration  
Ondansetron will be administered on both ar ms of the protocol at 8 mg p.o, daily  on Days 1-  42 days, 
30-60 minutes prior to each dose of chemothera py. A prescription for Ondansetron 8 mg p.o.  daily 30-
60 minutes before temozolomide X 7 days (with 6 refills) will be provided by provider . 
10.7.4  Drug Ordering  
Ondansetron is commercially available and will not be provided in this study.  A prescription for 
Ond ansetron will be given to the patient on both arms of the study.  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 36 of 52 
CONFIDENTIAL 
 11 SUBJECT ELIGIBILITY  
11.1 Inclusion Criteria  
Selection of Subjects: Patients with a malignant glioma who plan to undergo standard RT with concomitant 
daily temozolomide (TMZ) therapy . 
 
Please refer  to section 5.4 for a complete listing of the Inclusion Criteria.  
 
  
11.2 Exclusion Criteria  
 Please refer to section 5.4 for a complete listing of the Exclusion Criteria.  
  
12 SCREENING AND ON -STUDY TESTS AND PROCEDURES  
Patients will be initially screened durin g the -28 to 0  days prior to study initiation. During this time period , the 
following will be recorded: physical examination; vital signs and weight; laboratory studies (complete blood count 
with differential, platelet, blood chemistries, liver function t ests and urinalysis) ; past medical history; concomitant 
medications (steroids and anticonvulsants) ; and predictors of RINV (e.g. irradiation site, planned dose, treatment 
field,  alcohol intake, gender, age). Prior to study enrollment, patient's medications  should be reviewed by the 
clinical pharmacist to prevent concerns with drug interactions.  The patient’s medications  will be evaluated by the 
PI, the patient’s study physician, and/or the study pharmacist on a case by case basis for  safety.  Laboratory 
evaluations, performance status, concomitant medications, and adverse events for final eligibility should be 
confirmed within 2 weeks of initiating radiation with concomitant TMZ . 
 
Patients will be filling out data collection tools (i.e. MAT and TSMQ- 9) day 0  (baseline) and days 1, 2, 4, and 7 (for 
days 7, 1, 2- 3, and 4- 6, respectively)  of each week of radiation therapy.  In addition , they will be recording their 
medication and the use of rescue medication in a medication log  as noted below (See Section  12.7 and appendices  
for study tools).  
 
The CRC will be collecting data from the tools listed below and placing data in an electronic database that is 21CFR 
Part 11 compliant (e.g. Medidata Rave ).  Monthly  meetings between the CRC and primary investigators will occur 
to review data.  Patient Surveys and follow up phone calls will be conducted weekly to obtain and validate data.  
The CRC is required to  monitor protocol patients weekly or as many times as necessary to obtain toxicities.  
Toxicities are obtained via clinical notes or telephone conversations with the local oncology office and/or patient.  
The National Cancer Institute (NCI) Common Toxicity  Criteria (CTC) Version 4 is to be used to score the adverse 
advents . All graded toxicities are then entered in the database and reviewed together with the Primary 
Investigator (PI) and CRC and confirmed by source documents. Attributions are approved by primary investigators.  
 
 
 
 
 
  
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 37 of 52 
CONFIDENTIAL 
 Table 7: Screening and Study -related Tests and Procedures  
Phase  Screen  Start  Study Period  End 
 
Week of radiation  -4 to 0 1 2 3 4 5 6 
Days of radiation  -28 to 0 1-7 8- 14 15-21 22-28 29-35 36-42 
Genera l Evaluation s        
Informed Consent  X       
Eligibility Criteria  X5       
Past Medical History  
(RINV predictors)       
X       
Physical Exam  X       
Height, Weight, BSA  X       
Vital Signs  X       
Performance Status  X2       
Concomitant Medication s X2 X      
Adverse Events  X2 Continuous1 
Laboratory Evaluations         
CBC with Platelets  X2       
Serum Chemistry tests  X2       
Liver Function tests  X2       
Serum Pregnancy Test  X2                         
Urinalysis  X2       
Treatment         
Sequence A: Rolapitant  (Day)         X(22)    
Sequence B: Rolapitant  (Day)   X(1)      
Sequence A/B: Daily Ondansetron   X(1-
7) X (8-
14) X(15 -
21) X(22-28) X(29-
35) X(36-
42) 
Concomitant Temozolomide   X X X X X X 
Surveys /Medication log         
Medication L og  X X X X X X 
MAT Survey (Day 0  (baseline) and Days 
1,2,4,7/week )3 X X X X X X X 
TSQM9 Sequence A for wks1 -3; 4-6         X(22)4   X(43)4 
TSQM9 Sequence B  for wks1 -3; 4-6     X(22)4  X(43)4 
1. Adverse events will  be monitored until at least 30 days after the dose of Rolapitant ( or 2 weeks after the end of radiation)  
2. Laboratory evaluations, performance status, concomitant medications, and adverse events  for final eligibility should be confirmed 
within 2 weeks of initiating radiation with concomitant  TMZ.   
3. MASCC questionnaire on D ay 0 (baseline), and Days 1 , 2, 4, and 7 (for days 7, 1, 2- 3, 4-6, respectively)  
                    4. TSMQ -9 administered after week 3 (Day 22) and after week 6 of  radiation (Day 43) 
5. Eligibility criteria should be che cked after informed consent ( -4 to 0 weeks) and should be confirmed within 2 weeks of initiating 
radiation and concomitant TMZ.  
12.1 Screening Examination  
The screening examination will take place between Day - 28 and 0. Laboratory evaluations, performance 
statu s, concomitant medications, and adverse events  will be confirmed within 2 weeks of initiating radiation 
and concomitant TMZ .  An informed consent will be signed by the patient before any screening procedure 
takes place.  Subject data to be collected at th e Screening Examination as listed above in Table 7  includes  the 
following:  physical examination; vital signs and weight; laboratory studies (complete blood count with 
differential, platelet, blood chemistries, live r function tests , urinalysis,  and Beta -HG); past medical history; 
concomitant medications (steroids and anticonvulsants) ; and predictors of RINV (e.g. irradiation site, planned 
dose, treatment field, alcohol intake, gender, age).   
 
If a subject is found to be ineligible to participate in the study, minimal records regarding the subject and the 
reason for screen failure will be retained in the study database.  
12.2 Treatment Period  
The treatment period will consist of six weeks of radiation and concomitant temozolomide as previously described above. Sequence A involves administration of ondansetron alone for 3 weeks followed by the use of 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 38 of 52 
CONFIDENTIAL 
 rolapitant X 1 dose plus  daily  ondansetron for 3 weeks; whereas , sequence B involves the use of rolapitant X 1 
dose plus daily ondansetron for 3 weeks followed by 3 weeks of daily ondansetron alone.   For the rolapitant 
plus ondansetron weeks (1 or 4), patients will self -administer the oral rolapitant pill 1-2 hours  before the first 
radiation fraction on the  plan ned week  (see schem a). Subjects will be given a prescription for ondansetron 
8mg pills to be taken 30 minutes before their TMZ dose.  After the start of radiation therapy , the type of 
additional rescue antiemetic medication , if needed,  will be up to the investigator’s discretion.  Subjects will be  
informed  that they are allowed to take rescue antiemetic medication in either arm.  If the subject experiences 
nausea and vomiting and does take a rescue antiemetic, the subject will be asked to record the use of 
additional antiemetic  in a medication log provided to them . Subjects will complete weekly med ication log s and 
surveys (see appendices ) to capture study outcomes. Subjects will be told that the study is voluntary and that 
they may exit at any time if they wish.  
12.3 End of Tr eatment 
The end of treatment will occur at the last day of radiation therapy and will include the weekly study 
assessments outlined above (s ee appendices ). 
12.4 Follow -up Period  
The follow-up period will consist of a two -week period following chemoradiation treatment  (or at least 30 
days from the last dose of rolapitant in Sequence A)  in order to identify and collect any additional toxicity 
during this time.   
12.5 End of Study  
The study will be considered complete once enrollment has been met, follow -up procedures on all subjects 
have been conducted, and data analysis is concluded.  The study may also be terminated early for any reason 
by the PI -sponsor.  In order to terminate the study with the Duke IRB, all d ata extraction and analysis must be 
complete.  Therefore, if any articles for publication are derived from the current study, they must be 
submitted and accepted with no further need for additional data review prior to termination with the IRB.  
 Subjects t hat are lost to follow -up will be documented in the patient record and in the  21 CFR Part 11  
compliant database (e.g. Medidata Rave). In the eCRF , the subject will be marked at “Patient Status 
Unknown,” along with a corresponding explanation, if any.  This  status may also be documented on an  “Off 
Study Form” in the eCRF . 
12.6 Early Withdrawal of Subject(s)  
12.6.1  Criteria for Early  Withdrawal  
Subjects may voluntarily withdraw from the study at any time.  The PI may also withdraw a subject from 
the study at any time based on his/her discretion.  Reasons for PI -initiated  withdrawal may include, but 
are not limited to the following:  
- Adverse events or intolerable symptoms  
- Abnormal laboratory values  
- Abnormal test procedure results  
- Protocol deviation  
- Administrative issues 
- Pregnancy 
- Non- compliance of the subject  
12.6.2  Follow -up Requirements for Early  Withdrawal  
Subjects who prematurely withdraw  due to toxicity  will be followed for two weeks after a subject is 
removed from the study. End of study requirements outlined above will be co nducted . 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 39 of 52 
CONFIDENTIAL 
 12.6.3  Replacement of Early  Withdrawal (s) 
Not applicable  
12.7 Study Assessments  
12.7.1  Medical History  
Standard medical history assessments will be conducted and recorded per institutional guidelines.  Past 
medical history will include predictors of RINV (e.g. irradi ation site, planned dose, treatment field, 
alcohol intake, gender, age  etc.). The MAT  survey will capture known pa tient reported predictors (see 
appendices ). 
12.7.2  Physical Exam  
Standard physical exam and neurological assessment wi ll be conducted and documented per 
institutional and PRTBTC guidelines.  
12.7.3   MASCC Antiemesis Tool (MAT)  
The MAT is a validated , reliable  and easy -to-use clinical tool consisting of an  eight -item assessment of 
acute and delayed CINVCR rates.18 It was developed by the Multinational Association of Supportive Care 
in Cancer (MASCC) members to assist patients and oncology professionals in communicating accurately 
about the prevention and control of nausea and vomiting that may occur with chemotherapy.   The 
concept of the MAT is to provide an easy -to-use and easy -to-evaluate tool to assist in providing the best 
individual care to patients.  Additionally, the tool was designed to  aid treatment centers in 
understanding the eff ectiveness of their antiemetic strategies.  The internal consistency reliability of the 
scale was high, with Cronbach alphas of 0.77 (patient sample) and 0.82 (care -giver sample). Responses 
were similar between the UK and U.S. samples in terms of nausea and  vomiting, and both samples 
found the scale easy to use. Contrasted -groups validity (using age as a grouping variable) and 
concurrent validity (MAT compared with Rhodes Index for nausea, vomiting and retching - INVR) 
suggested that the scale is sensitive to  detect the different dimensions of CINV and performed well 
against a daily assessment of nausea/vomiting (total score correlation r=0.86, P<0.001). Recall of events 
was high even three weeks after chemotherapy (correlations with INVR of 0.44 -0.99, all P<0 .01). Factor 
analysis clearly identified three factors, namely vomiting, acute nausea, and delayed nausea. Proxy assessments by care givers were congruent with the patients' responses, especially in relation to 
vomiting. The MAT facilitate s discussion betwe en clinicians and patients about their nausea and 
vomiting experience, thereby potentially aiding treatment decisions.  Assessment s of CINV CR rates  are 
conducted at baseline and weekly on d ays 1, 2, 4 and 7, and ultimately will capture data for all days a  
patient is in the study (See Section 12 and appendices
). 
12.7.4  Treatment Satisfaction Questionnaire for Medication (TSMQ -9)  
To evaluate patie nt preference f or the combination of rolapitant plus ondansetron vs. ondansetron 
alone, the patients will fill out the valid TSMQ-9 questionnaire for week s 1-3 and week s 4-6 (see 
schema) .  Analysis of the  patient satisfaction or preference endpoint can be found in Section 15.5.2. 
 The 14 -item Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 is a reliable and 
valid instrument to assess patients' satisfaction with medication, providing scores on four scales – side 
effects, effectiveness, convenience and global satisfaction .
16 In naturalistic studies, administering the 
TSQM with the side effects domain was thought to provoke the physician to assess the presence or absence of  adverse events in a way that is clinically atypical, carrying the potential to interfere with 
routine medical care.  As a result, an abbreviated 9- item TSQM (TSQM -9), derived from the TSQM 
Version 1.4 but without the five items of the side effects domain was created.
16 In a study using an 
interactive voice response system (IVRS) -administered TSQM -9, it was psychometrically evaluated 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 40 of 52 
CONFIDENTIAL 
 among patients taking antihypertensive medication. TSQM -9 domains had high internal consistency as 
evident from Cronbach's al pha values of 0.84 and gre ater.16  TSQM -9 domains al so demonstrated good 
test-retest reliability with high intraclass correlation coefficients exceeding 0.70.16 As expected, the 
TSQM -9 domains were able to differentiate between individuals who were low, medium and high 
compliers of medication, with moderate to high effect sizes.16  There was evidence of conv ergent 
validity with significant correlations with the medication adherence scale.16  The TSQM -9 was found to 
be a reliable, valid tool  to assess treatment satisfaction in naturalistic study designs, in which there is 
potential that the administration of the side effects domain of the TSQM would interfere with routine 
clinical care.  
13 SAFETY MONITORING AND REPORTING  
The PI is responsible for the identification and documentation of adverse events and serious adverse events, as 
defined below.  At each study visit, the PI or designee mus t assess, through non -suggestive inquiries of the subject 
or evaluation of study assessments, whether an AE or SAE has occurred.  
13.1 Adverse Events  
An adverse event (AE) is any untoward medical occurrence in a subject  receiving study drug  and which does 
not ne cessarily have a causal relationship with this treatment.   For this protocol, the definition of AE also 
includes worsening of any pre -existing medical condition  and the onset of new illness.  An AE can therefore be 
any unfavorable and unintended or worseni ng sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of rolapitant plus ondansetron vs ondansetron alone  whether or 
not related to use of the  rolapitant plus ondansetron vs ondansetron alone.  But labor atory value changes that 
require therapy or adjustment in prior therapy are considered adverse events.  
 
From the time the subject signs the informed consent form through the End of Study visit (as defined in 
Section 12.5), all AEs must be recorded in the subject medical record and adverse events case report form. 
 AEs will be assessed according to the CTCAE version 4.  If C TCAE grading does not  exist for an AE, the severity 
of the  AE will be graded as mild (1), moderate (2), severe (3), life -threatening (4), or fatal (5).  
 Attribution of AEs will be indicated as follows:  
- Definite:  The AE is clearly related to the study drug  
- Probably:  The AE is likely related to the study drug  
- Possible:  The AE may be related to the study drug  
- Unlikely:  The AE is doubtfully related to the study drug  
- Unrelated:  The AE is clearly NOT related to the study drug  
13.1.1  
Reporting of AEs  
Not required by sponsor  
13.2 Serious Adverse Events  
An AE is conside red “serious” if , in the opinion of the investigator ,  it is one of the following  outcomes *: 
- Fatal  
- Life-threatening  
- Constitutes a congenital anomaly or birth defect  
- A medically significant condition (defined as an event that compromises subject safety or m ay 
require medical or surgical intervention to prevent one of the three outcomes above).  
- Requires inpatient hospitalization or prolongation of existing hospitalization  
- Results in persistent or significant incapacity or substantial disruption to conduct nor mal life 
functions.  
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 41 of 52 
CONFIDENTIAL 
 *Exception: Preplanned (at time of informed consent) hospitalization for elective procedures, for protocol 
compliance or social reasons, or for observation will not be considered criteria for an SAE. The reason for the 
planned hospital ization should be documented. Complications experienced during these hospitalizations must 
be reported as SAEs if hospitalization is prolonged due to AE, or if the complication meets other serious criteria. 
13.2.1  
Reporting of SAEs  
Only adverse events that the Du ke Sponsor -Investigator determines to be serious, unanticipated, and 
related or possibly/probably (i.e. more likely than not) related to the research must be reported to the 
Duke IRB.  Those adverse events will be submitted in the electronic IRB system, ac cording to the 
following guidelines:  
• Report within 24 hours of learning about any subject’s death that was unanticipated and 
more likely related to the research than unrelated;  
• Report within 5 business days of learning about any serious, unanticipated, and  related or 
possibly/probably related adverse event;  
• Report within 10 business day of learning about any other unanticipated problem or event 
that was more likely related to the research than unrelated. 
13.2.1.1     Reporting to TerSera  
Serious adverse events that t he Duke Sponsor -Investigator determines to be serious 
and related to rolapitant is to be shared with TerSera via MedWatch or CIOMS I form within 3 working days  of Investigator awareness. If supporting documentation is 
included in the submission to TerSera (e.g., hospital reports, consultant reports, death 
certificates, autopsy reports, etc.), please redact any patient identifiers (including 
Medical Record number).  
 
TerSera SAE Contact Details  
• Email: TESAROPV@UBC.com
 
• Fax: 1.866.750.6823  
13.2.2  Reporting Product Complaints for TerSera Products  
Any written, electronic or oral communication that alleges dissatisfaction related to manufactured clinical drug product with regards to its manufacturing, testing, labeling, packaging, or shipping, must 
be reported by the Sponsor Institution or qualified designee to TerSera Call Center (US Call center: 
TerSera@medinfodept.com
) within 1 working day of first becoming aware of the possible defec t.  This 
report to TerSera may also be made by telephone to the designated TerSera representative (1 -844-483-
7276) or by fax to the Call Center (1 -913-451-6409).   The product and packaging components in 
question, if available, must be stored in a secure ar ea under specified storage conditions until it is 
determined whether the product is required to be returned for investigation of the defect.  If the 
product complaint is associated with an SAE, the SAE must be reported separately in accordance with 
the pro tocol, and the SAE report should mention the product quality complaint.  
 
13.3 Special Warnings and Precautions  
Not Applicable  
13.4 Safety Oversight Committee (SOC)  
The Duke Cancer Institute SOC is responsible for annual data and safety monitoring of DUHS sponsor -
investigator phase I and II, therapeutic interventional studies that do not have an independent Data Safety 
Monitoring Board (DSMB). The primary focus of the SOC is review of safety data, toxicities and new 
information that may affect subject safety or effica cy. Annual safety reviews include , but may not be limited 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 42 of 52 
CONFIDENTIAL 
 to, review of safety data, enrollment status, stopping rules if applicable, accrual, toxicities, reference 
literature, and interim analyses as provided by the sponsor -investigator.  The SOC in conce rt with the DCI 
Monitoring Team (see Section 14.1 for Monitoring Team description) oversees the conduct of DUHS cancer -
related, sponsor -investigator greater -than -minimal- risk intervention studies that do not have an external 
monitoring plan, ensuring subject safety and that the protocol is conducted, recorded and reported in 
accordance with the protocol, standing operating procedures (SOPs), Good Clinical Practice (GCP), and 
applica ble regulatory requirements.  
14 QUALITY CONTROL AND QUALITY ASSURANCE 
14.1 Monitoring  
The Duke Cancer Institute ( DCI) Monitoring Team will conduct monitoring visits to ensure subject safety and to 
ensure that the protocol is conducted, recorded, and reported in ac cordance with the protocol, standard 
operating procedures, good clinical practice, and applicable regulatory requirements.  As specified in the DCI 
Data and Safety Monitoring Plan, the DCI Monitoring Team will conduct routine monitoring after the third 
subject is enrolled, followed by annual monitoring of 1 – 3 subjects until the study is closed to enrollment and 
subjects are no longer receiving study interventions that are more than minimal risk.   
 
Additional monitoring may be prompted by findings from mo nitoring visits, unexpected frequency of serious 
and/or unexpected toxicities, or other concerns and may be initiated upon request of DUHS and DCI 
leadership, the DCI Cancer Protocol Committee, the Safety Oversight Committee (SOC), the sponsor, the 
Princip al Investigator, or the IRB.  All study documents must be made available upon request to the DCI 
Monitoring Team and other authorized regulatory authorities, including but not limited to the National Institute of Health, National Cancer Institute, and the FDA.  Every reasonable effort will be made to maintain 
confidentiality during study monitoring.  
14.2 Audits  
The Duke Office of Audit, Risk and Compliance  (OARC ) office may conduct  confidential  audits to evaluate 
compliance with the protocol and the principles o f GCP.  The PI agrees to allow the OARC  auditor(s)  direct 
access to all relevant documents and to allocate his/her time and the time of the study team to the OARC  
auditor(s) i n order to discuss findings and any relevant issues.  
 
OARC  audits are designed to  protect the rights and well -being of human research subjects. OARC A audits may 
be routine or directed (for cause). Routine audits are selected based upon risk metrics generally geared 
towards high subject enrollment, studies with limited oversight or moni toring, Investigator initiated 
Investigational Drugs or Devices, federally -funded studies, high degree of risk (based upon adverse events, 
type of stud y, or vulnerable populations), phase 1  studies, or studies that involve Medicare populations. 
Directed au dits occur at the directive of the IRB or an authorized Institutional Official.  
 
OARC  audits examine research studies/clinical trials methodology, processes and systems to assess whether 
the research is conducted according to the protocol approved by the DUHS IRB. The primary purpose of the 
audit/review is to verify that the standards for safety of human subjects in clinical trials and the quality of data 
produced by the clinical trial research are met. The audit/review will serve as a quality assurance mea sure, 
internal to the institution. Additional goals of such audits are to detect both random and systemic errors 
occurring during the conduct of clinical research and to emphasize “best practices” in the research/clinical 
trials environment.  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 43 of 52 
CONFIDENTIAL 
 14.3 Data Managemen t and Processing  
14.3.1  Case Report Forms (CRFs)  
The electronic CRF will be the primary data collection document for the study.  The CRFs will be 
updated in a timely manner following  acquisition of new source data.  Only approved study staff  (the PI, 
the research  coordinators, the research nurses, the data management team, and the clinical trials 
manager ), are permitted to make entries, chang es, or corrections in the CRF.  
 
An audit trail will be maintained automatically by the electronic CRF management system , which will be 
a 21 CFR Part 11 compliant database  (e.g. Medidata Rave) .  Designated personnel  will complete user 
training, as required or appropriate per regulations. 
14.3.2  Data Management Procedures and Data Verification 
Designated personnel (e.g. the data managem ent team and the clinical trials manager) using the 
electronic CRF will have access based on their specific roles in the protocol.    
 Completeness of entered data will be checked automatically by the eCRF system, and users will be 
alerted to the presence o f data inconsistencies.  Additionally, the data management team and the 
statistical team  will cross- reference the data to verify accuracy.  Missing or implausible data will be 
highlighted for the PI requiring appropriate responses (i.e. confirmation of data, correction of data, 
completion or confirmation that data is not availab le, etc.).  
 
The database will be reviewed and discussed prior to database closure, and will be closed only after 
resolution of all remaining queries.  An audit trail will be kept of all subsequent changes to the data.  
14.3.3  
Study Closure  
Following completion of the studies, the PI will be responsible for ensuring the following activities:  
- Data clarification and/or resolution  
- Accounting, reconciliation, and destruction/return of used and unused study drugs  
- Review of site study records for completeness 
- Shipment of all remaining laboratory sample s to the designated laboratories  
15 STATISTICAL METHODS AND DATA ANALYSIS 
All statistical analysis will be performed under the direction of the statistici an designated in key personnel.  Any 
data analysis carried out independently by the investigator must be approved by the statistician before publication 
or presentation. 
15.1 Analysis Sets 
The analysis of the complete response endpoint will focus on all patient s randomized to sequence A or B.  
However, the analysis of the patient preference endpoint will focus on those patients who have experienced 
both regimens and provided a preference assessment.  Safety analyses will include all patients who receive 
protocol  treatment . 
15.2 Patient Demographics and Other Baseline Characteristics  
The socio -demographic and clinical characteristics of all randomized patients  will be summarized by sequence 
assignment  using means/SD, medians, percentiles, frequencies/proportions.  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 44 of 52 
CONFIDENTIAL 
 15.3 Treatments  
Within each sequence assignment, a frequency distribution will be generated for the number of weeks of anti -
emetic therapy received when ondansetron was administered alone, and when ondansetron wa s 
administered with rolapitant.  
15.4 Primary Objective 
The primary objective of this study is to compare the efficacy of rolapitant plus ondansetron vs. ondansetron 
alone in the prevention of nausea and vomiting, as measured by the overall complete response rate, among 
malignant glioma patients during RT and conco mitant TMZ  (see Section 8). 
 
As described in Sections 15.6 and 15.7, the study was originally designed to enroll 170 glioma patients with the 
expectation that 160 patients w ould  be randomized to receive one of two treatment sequences of anti -emetic 
therapy for the prevention of nausea and vomiting associated with RT and concomitant TMZ.   A formal 
interim analysis was planned after 80 patients had been randomized (i.e.  40 patients to each treatment 
sequence).  As of mid- January 2022, 53 patients had been randomized.  On January 18,  2022, TerSera, the 
study’s funding source, requested that accrual to the study be terminated in the next few months.  
 
Given this request fro m TerSera, the accrual target for this study is reduced to 57 patients.  The decision to 
terminate early has not been  influenced by the data collected to date , as no interim analyses have been 
conducted.  The a nalyses as described below will be conducted; however, they may no longer have the power 
to detect the hypothesized effect size.  
15.4.1  Variable  
Complete response (CR) rate associated with rolapitant plus ondansetron and that associated with 
ondansetron during the first two weeks of RT and concomitant TMZ  is defined as the proportion of 
patients with no emetic episode or use of rescue medication while receiving radiation and concomitant TMZ .
 The CR rate will be assessed via the modified MASCC Antiemesis Tool (MAT).17  
15.4.2  Statistical Hypothesis, Model, and Method of Analysis  
As the primary analysis, a chi -square test will compare treatment regimens (ondansetron alone vs 
rolapitant + ondansetron) with respect to the proportion  of patients who experience a CR during 
the first 2 weeks of RT and TMZ treatment.  As an additional analysis, logistic regression will assess the effect of potential confounders on this relationship.  Among the covariates that will be 
considered is the do se of decadron administered during the 2 weeks of RT and TMZ treatment.  
 
As an exploratory analysis, a generalized linear model with a logit link that accounts for correlation 
between the CR status observed during the first and second treatment period within the same 
patient will be used to assess the impact of period, treatment, and their interaction.  The purpose 
of this latter analysis is to assess whether the incremental effect of combination treatment relative 
to ondansetron alone is the same whether r olapitant is administered during the first period (i.e. 
first 3 weeks) or the second period (i.e. the second 3 -week treatment regimen).  It should be noted 
that this test will have low power to detect a clinically meaningful interaction effect. Within the 
context of the generalized linear model described above, the impact of covariates on CR rate will 
be explored. Included among these covariates will be the dose of decadron administer during that 
segment of the treatment regimen.  
15.5 Secondary Objectives  
 
Please refer to Section 8 for the  secondary objectives and endpoints.  The key secondary objective is to assess 
whether malignant glioma patie nts receiving RT and concomitant TMZ are more satisfied with rolapitant pl us 
ondansetron vs. ondansetron for the prevention of RINV.  Other s econdary objectives include: (1) To describe 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 45 of 52 
CONFIDENTIAL 
 the rationale behind a patient’s satisfaction with antiemetic preference based upon effectiveness, 
convenience, and global satisfaction, (2) To evaluate patient compliance with rolapitant plus ondansetron and 
ondansetron alone, and (3) To assess the safety of rolapitant plus ondansetron in the prevention of RINV in primary glioma patients receiving RT and concomitant TMZ.  
15.5.1  
Key Secondary Objective 
The percentage of patients who prefer rolapitant plus ondansetron over ondansetron, as 
determined by response to the question with “Which nausea medication regimen was I most 
satisfied with?” will be calculated, with a 95% confidence interval.  An exact bin omial test assessing 
whether the proportion preferring the treatment regimen that includes rolapitant is 0.5 will be 
conducted.  Logistic regression will explore the potential that sequence influences patient 
preference.  
15.5.2  Other Secondary Objectives  
Mean patient satisfaction scores for effectiveness, convenience and global satisfaction, will be computed based upon responses to the TSQM -9 treatment satisfaction survey
16  that patients 
complete at the end of week 3 after treatment with ondansetron alone or  combination  treatment.  
Three subscales will be computed:  effectiveness (3 items), convenience (3 items), and global 
satisfaction (3 items).  Assuming there is no evidence of a carry -over effect, a paired t- test will be 
conducted comparing satisfaction with combination treatment and with ondansetron treatment 
alone.  
 The efficacy of rolapitant plus ondansetron vs. ondansetron monotherapy  in the prevention of 
nausea and vomiting  will be separately assessed , as measured by the respective CIN, CIV CR  rates, 
among malignant glioma patients during RT and concomitant TMZ . The CR outcome for nausea will 
be defined as no use of rescue medication for nausea, while t he CR outcome for vomiting will be 
defined as no use of rescue medication for vomiting.  The CIN and CIV CR rate s will be assessed v ia 
the modified MASCC Antiemesis Tool (MAT) . 
 
For each 3- week treatment regimen, compliance is defined as the percentage of days that pills 
were appropriately used. The distribution of compliance during treatment with ondansetron alone 
and with combination  treatment will be described with a frequency distribution.  A nonparametric 
paired test (e.g. Wilcoxon) may be used to compare compliance within  the two regimens (as 
documented on the medication logs).  
 For the manuscript, adverse events that are possibly , probably, and definitely treatment related 
that are reported during the ~ 6 weeks  of treatment will be summarized.  For each type of adverse 
event experienced by a patient during rolapitant plus ondansetron and during ondansetron 
treatment, the maximum g rade experienced by each patient will be tabulated by treatment group 
(i.e. rolapitant plus ondansetron or ondansetron treatment).  Given the cross -over design of this 
study, patients will contribute data to both  treatment groups. Two tabulations of toxici ty data will 
be generated for review by the Safety Oversight Committee including one that includes all toxicities 
regardless of attribution, and another that includes only toxicities that are possibly, probably, and 
definitely related to protocol treatment.  For each of these tabulations, the maximum grade of 
each type of toxicity experienced by each patient will be summarized with frequency distributions 
within each treatment (rolapitant plus ondansetron vs. ondansetron).  For ClinicalTrials.gov, serious 
adverse events and other adverse events will be summarized separately. These tabulations will 
reflect the number of patients who experience each type of toxicity regardless of grade or 
attribution.  
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 46 of 52 
CONFIDENTIAL 
 15.6 Interim Analysis  
Original Study Design :  An interim efficacy analysis will be conducted after 40 patients are randomized to each 
sequence  (a total of 80 patients) .  Given that the interim analysis will primarily focus on the complete 
response endpoint, study accrual  will be suspended for  approximately 2 weeks while  the initial outcome data 
from all patients is collected.   This interim analysis will allow early accrual termination for efficacy or for 
futility.   
 
The O’Brien -Fleming analogue will define t he alpha and beta spending function.  The group sequential 
procedure for proportions within PASS has been used to simulate the following boundaries for comparing the 
CR rate in the two groups using a large -sample Z -test.19,20 
 
 Significance Boundary  Futility Boundary  
Look  Z-Value Scale  P-value Scale  Z-Value Scale  P-Value Scale  
1 (after 80 patients)  2.505  0.006  0.325  0.373  
2 (after 160 patients)  1.657  0.049  1.657  0.049  
 
At the time of the interim analysis, the combination would be considered superior to ondansetron 
monotherapy if the p -value was less than 0.006 an d accrual terminated.  If, on the other hand , the p -value 
associated with this comparison was 0.373 or larger, there would be a recommendation that accrual be terminated early due to futility.   
 These boundaries will be used as guidance in determining whether patient accrual should be terminated early.  
Other issues may also factor into that decision -making.  
 
Modified Study Design: With the reduction in the study’s accrual target as described in Section 15.4, no 
interim analyses are planned.  
15.7 Sample Size Calculation  
15.7.1  Original Study Design  
One h undred seventy (170) glioma patients will be enrolled with the expectation that 160 patients 
will be randomized to receive one of two treatment sequences of anti -emetic therapy for the 
prevention of nausea and vomiting associated with RT and concomitant TMZ.   A permutated block 
randomization with an allocation ratio of 1:1 will be used to assign patients to sequence A or B.  Sequence A involves a 3- week regimen of daily ondansetron followed by a 3 -week regimen 
consistin g of rolapitant (day 22 only) and daily ondansetron; whereas Sequence B involves a 3-
week regimen of rolapitant (day 1 only) and daily ondansetron followed by a 3 -week regimen of 
daily ondansetron.   The study has one primary and one KEY secondary endpoint :  CR rate and 
patient overall preference for ondansetron treatment with or without rolapitant.  Though the primary CR rate endpoint will focus on treatment during the first 2 weeks of RT and TMZ, a cross-
over design is proposed so that a patient will expe rience both modes of treatment, and be 
equipped to make a comparative assessment of preference.   
 
Power Calculations for Complete Response , Primary  Endpoint :  The power of the comparison of 
ondansetron and the combination of ondansetron and rolapitant rel ative to the CR rate during the 
initial 2 weeks of treatment with RT and TMZ will be considered here.  This comparison will focus 
on the anti -emetic experience during the first regimen of the two treatment regimens that the 
patient will receive.  Let  
 
p1 = overall complete response rate for the first 2 weeks of treatment with the combination  
antiemetic regimen , and  
 
Pro00076418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 47 of 52 
CONFIDENTIAL 
 p0 = overall complete response rate during the first 2 weeks of treatment with ondansetron alone.   
 
The hypothesis that will be assessed is w hether the CR rate with combination treatment is greater 
than that with ondansetron alone.  Specifically, the hypothesis that will be tested is as follows:       
 
H0: p1 ≤ p 0 versus H1: p 1 > p 0 
 
Temozolomide prescribing information reports a vomiting rate of 20% with concomitant RT + TMZ.  
Anti-emetic treatment failure includes the occurrence of vomiting or the use of an anti- emetic for 
nausea and/or vomiting.  Therefore, we anticipate that approximately 25% of patients receiving ondansetron alone to either vomit or receive an anti- emetic.  Equivalently, a CR rate of 75% is 
anticipated with ondansetron alone.  
 One hundred sixty (160) patients will be randomized to either se quence A or B with the expectation 
that 152 patients will provide an assessment of their experience during the first 2 weeks of treatment with the first regimen.  With 152 patients, there is 80% power to detect an increase in 
the CR rate from 75% with ondansetron to 90% with the combination of ondansetron and 
rolapitant (α=0.05; one -tailed).  
 
Power Calculations for Patient Preference , KEY Secondary Endpoint : The hypothesis of this study is 
that patients will prefer the combination of ondansetron and rolapitant over ondansetron alone for 
the prevention of nausea and vomiting.  If no overall preference exists, then the percentage of 
patients who choose combination treatment is expected to be approximately 50%.  The hypothesis 
that will be tested is whether the  proportion of patients who prefer combination treatment is 
greater than 50%.  Statistically, the hypothesis that will be tested is:  
 
H0: p ≤ 0.5 vs H1: p > 0.5  
 
where p is the proportion of patients who prefer combination treatment over ondansetron alone .  
Under the assumption that approximately 140 patients will have experienced both regimens and provided a preference assessment, the study has 93% power to detect a preference rate of 65% or 
greater with a two- tailed test conducted at the 0.05 level of significance.  
15.7.2  
Modified Study Design 
As described in Section 15.4, the sample size goal for this study is reduced to 57 patients.  With 57 patients, there is 80% power to detect an increase in the CR rate from 75% with ondansetron to 97% with the combination of ondansetron and rolapitant (α=0.05; one -tailed).   Alternatively, there 
is 80% power to detect an increase in CR rate from 63% to 90%.  
 
Relative to patient preference, with 57 patients, the study has 83% power to detect a preference 
rate of 6 9% or greater with a two-tailed test condu cted at the 0.05 level of significance.  
16 ADMINISTRATIVE AND ETHICAL CONSIDERATIONS  
16.1 Regulatory and Ethical Compliance 
This protocol was designed and will be conducted and reported in accordance with the International Conference on Harmonization (ICH) Harmoni zed Tripartite Guidelines for Good Clinical Practice, the 
Declaration of Helsinki, and applicable federal, state, and local regulations. 
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 48 of 52 
CONFIDENTIAL 
 16.2 DUHS Institutional Review Board and DCI Cancer Protocol Committee 
The protocol, informed consent form, advertising mate rial, and additional protocol -related documents must 
be submitted to the DUHS Institutional Review Board (IRB) and DCI Cancer Protocol Committee (CPC) for 
review.  The study may be initiated only after the Principal Investigator has received written and da ted 
approval from the CPC and IRB.  
 
The Principal Investigator must submit and obtain approval from the IRB for all subsequent protocol 
amendments and changes to the informed consent form.  The CPC should be informed about any protocol 
amendments that pote ntially affect research design or data analysis (i.e. amendments affecting subject 
population, inclusion/exclusion criteria, agent administration, statistical analysis, etc.).  
 
The Principal Investigator must obtain protocol re -approval from the IRB within  1 year of the most recent IRB 
approval.  The Principal Investigator must also obtain protocol re -approval from the CPC within 1 year of the 
most recent IRB approval, for as long as the protocol remains open to subject enrollment.  
16.3 Informed Consent  
The info rmed consent form must be written in a manner that is understandable to the subject population.  
Prior to its use, the informed consent form must be approved by the IRB.  
 
The Principal Investigator or authorized key personnel will discuss with the potentia l subject the purpose of 
the research, methods, potential risks and benefits, subject concerns, and other study -related matters.  This 
discussion will occur in a location that ensures subject privacy and in a manner that minimizes the possibility 
of coerci on.  Appropriate accommodations will be made available for potential subjects who cannot read or 
understand English or are visually impaired.  Potential subjects will have the opportunity to contact the Principal investigator or authorized key personnel  with questions, and will be given as much time as needed to 
make an informed decision about participation in the study.  
 Before conducting any study- specific procedures, the Principal Investigator must obtain written informed 
consent from the subject or a le gally acceptable representative.  The original informed consent form will be 
stored with the subject’s study records, and a copy of the informed consent form will be provided to the 
subject.  The Principal Investigator is responsible for asking the subject  whether the subject wishes to notify 
his/her primary care physician about participation in the study.  If the subject agrees to such notification, the 
Principal Investigator will inform the subject’s primary care physician about the subject’s participatio n in the 
clinical study.  
16.4 Study Documentation  
Study documentation includes but is not limited to source documents, case report forms (CRFs), monitoring 
logs, appointment schedules, study team correspondence with sponsors or regulatory bodies/committees, 
and regulatory documents that can be found in the DCI -mandated “Regulatory Binder”, which includes but is 
not limited to signed protocol and amendments, approved and signed informed consent forms, FDA Form 
1572, and CAP and CLIA laboratory certifications.  
 
Source documents are original records that contain source data, which is all information in original records of 
clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation of the trial.  Source doc uments include but are not limited to hospital records, clinical and office 
charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, copies or transcriptions cer tified after verification as being 
accurate copies, microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and 
records kept at the pharmacy, at the laboratories and at medico- technical departments involved in the clinical 
trial.  DUHS utilizes Epic Maestro Care as an electronic health record.  When possible, the original record 
should be retained as the source document.  However, a photocopy is acceptable provided that it is a clear, 
legible, and an exact duplication of the  original document.  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 49 of 52 
CONFIDENTIAL 
 16.5 Privacy, Confidentiality, and Data Storage  
The Principal Investigator will ensure that subject privacy and confidentiality of the subject’s data will be 
maintained.   Research Data Security Plans (RDSPs) will be approved by the appropria te institutional Site Based 
Research group.  
To protect privacy, every reasonable effort will be made to prevent undue access to subjects during the course 
of the study.  Prospective participants will be consented in an exam room where it is just the resea rch staff, 
the patient and his family, if desired. For all future visits, interactions with research staff (study doctor and 
study coordinators) regarding research activities will take place in a private exam room. All research related 
interactions with th e participant will be conducted by qualified research staff who are directly involved in the 
conduct of the research study.  
 
To protect confidentiality, subject files in paper format will be stored in secure cabinets under lock and key 
accessible only by t he research staff. Subjects will be identified only by a unique study number and subject 
initials.  Electronic records of subject data will be maintained using a dedicated 21 CFR Part 11 compliant  
database ( e.g. Medidata Rave) , which is housed in an encrypted and password -protected secure network 
drive .  Access to electronic databases (without edit rights) will be limited to the PI, the study coordinator, and 
the statistical team .  The only personnel with both access and edit rights to the electronic databa ses are the 
data management team, including the clinical trials manager.  The security and viability of the IT infrastructure 
will be managed by the DCI and/or Duke Medicine.   
 
Upon completion of the study, research records will be archived and handled pe r DUHS HRPP policy.     
 
Subject names or identifiers will not be used in reports, presentations at scientific meetings, or publications in 
scientific journals.  
16.6 Data and Safety Monitoring  
Data and Safety Monitoring will be performed in accordance with the DCI Data and Safety Monitoring Plan.  
For a more detailed description of the DSMP for this protocol, refer to Section 13.5 and 14.1.  
16.7 Protocol Amendments  
All protocol amendments must be initiated by the Principal Investigator and approved by the IRB prior to 
implementation.  IRB approval is not required for protocol changes that occur to prote ct the safety of a 
subject from an immediate hazard.  However, the Principal Investigator must inform the IRB and all other 
applicable regulatory agencies of such action immediately.  
 
Though not yet required, the CPC should be informed about any protocol amendments that potentially affect 
research design or data analysis (i.e. amendments affecting subject population, inclusion/exclusion criteria, agent administration, etc.).  
16.8 Records Retention  
The Principal Investigator will maintain study -related records fo r the longer of a period of:  
- at least two years after the date on which a New Drug Application is approved by the FDA (if an IND is 
involved)  
- at least two years after formal withdrawal of the IND associated with this protocol (if an IND is involved)  
- at least six years after study completion (Duke policy)   
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 50 of 52 
CONFIDENTIAL 
 17 REFERENCES  
 
 1. Feyer PC, Maranzano E, Molassiotis A, et al: Radiotherapy -induced nausea and vomiting (RINV): 
MASCC/ESMO guideline for antiemetics in radiotherapy: update 2009. Su pport Care Cancer 19 Suppl 1:S5 -14, 
2011 
 2. Maranzano E, De Angelis V, Pergolizzi S, et al: A prospective observational trial on emesis in 
radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94:36 -41, 
2010  3. Ramlov A, Tietze A, Khalil AA, et al: Prophylactic cranial irradiation in patients with small cell 
lung cancer. A retrospective study of recurrence, survival and morbidity. Lung Cancer 77:561 -6, 2012 
 4. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. New England Journal of Medicine 352:987- 96, 2005 
 5. Gralla RJ, Osoba D, Kris MG, et al: Recommendations for the use of antiemetics: ev idence- based, 
clinical practice guidelines. American Society of Clinical Oncology. Journal of Clinical Oncology 17:2971 -94, 1999 
 6. (NCCN): National Comprehensive Cancers Network: Clinical practice guidelines in oncology. , 
2011, 2012  7. Corp. MSD: Highl ights of prescribing information.Temodar® (temozolomide) Capsules, 
Temodar® (temozolomide) for injection, 2013  
 8. Bae SH, Park MJ, Lee MM, et al: Toxicity profile of temozolomide in the treatment of 300 
malignant glioma patients in Korea. J Korean Med Sci  29:980- 4, 2014 
 9. Gralla RJ RF, Tonato M, Herrstedt J: MASCC/ESMO Antiemetic Guideline 2013. Multinational 
Association of Supportive Care in Cancer [MASCC], Multinational Association of Supportive Care in Cancer [MASCC], 2013  
 10. Basch E, Prestrud AA, H esketh PJ, et al: Antiemetics: American Society of Clinical Oncology 
clinical practice guideline update. Journal of Clinical Oncology 29:4189 -98, 2011 
 11. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant 
temozolomid e versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5- year analysis 
of the EORTC -NCIC trial. Lancet Oncol 10:459 -66, 2009 
 12. Affronti ML, Woodring S, Allen K, et al: Phase II study to evaluate the safety and efficacy of 
intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ). Support Care Cancer, 2016  
 13. Feyer P, Jahn F, Jordan K: Prophylactic Management of Radiation -Induced Naus ea and Vomiting. 
Biomed Res Int 2015:893013, 2015 
 14. Rapoport BL, Chasen MR, Gridelli C, et al: Safety and efficacy of rolapitant for prevention of 
chemotherapy -induced nausea and vomiting after administration of cisplatin- based highly emetogenic chemotherapy 
in patients with cancer: two randomised, active -controlled, double -blind, phase 3 trials. Lancet Oncol 16:1079 -89, 
2015 
 15. Schwartzberg LS, Modiano MR, Rapoport BL, et al: Safety and efficacy of rolapitant for 
prevention of chemotherapy -induced nau sea and vomiting after administration of moderately emetogenic 
chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double -blind, phase 3 trial. Lancet Oncol 16:1071- 8, 2015 
 16. Bharmal M, P ayne K, Atkinson MJ, et al: Validation of an abbreviated Treatment Satisfaction 
Questionnaire for Medication (TSQM -9) among patients on antihypertensive medications. Health Qual Life 
Outcomes 7:36, 2009  
 17. Brearley SG, Clements CV, Molassiotis A: A revie w of patient self -report tools for chemotherapy -
induced nausea and vomiting. Supportive Care in Cancer 16:1213- 29, 2008 
 18. Molassiotis A, Coventry PA, Stricker CT, et al: Validation and psychometric assessment of a short 
clinical scale to measure chemoth erapy -induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom 
Manage 34:148 -59, 2007 
19.  O’Brien PC and Fleming TR:  A multiple testing procedure for clinical trials.  Biometrics 35:549 -
556, 1979 
              20.      PASS 14 Power Analys is and Sample Size Software (2015). NCSS, LLC. Kaysville, Utah, USA, 
ncss.com/software/pass.
  
Pro000 76418:  Rolapitant  
Version:   2/18/2022 
  
 Duke Cancer Institute  Page 51 of 52 
CONFIDENTIAL 
 18 APPENDICES  
18.1 Appendix 1: Sequence A -TSQM9/MAT Questionnaire  
Please see attached  
 
18.2 Appendix 2: Sequence B -TSQM9/MAT Questionnaire  
Please see attached        
 
18.3 Appendix  3: Medication Log :   Sequence A  
Please see attached  
 
18.4 Appendix 4: Medication Log :   Sequence B  
Please see attached  
18.5 Appendix 5: Birth Control Recommendations  
Please see attached  